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Abstract  
Medical imaging is an integral part of cancer management. Conventional medical imaging such 
as computed tomography provides anatomical images, which together with functional imaging 
may be used for depicting tumor properties of biological relevance. Positron Emission 
Tomography is one of the functional imaging methods which visualize metabolically active 
tissues. 
18
F-fluorodeoxyglucose (FDG) is the most common PET tracer in oncology. FDG-PET 
depicts glucose metabolism, which increases in most tumors because many cancer cells undergo 
a metabolic shift during tumor development towards increased glucose metabolism. In addition 
to cancer, normal healthy tissue will also accumulate FDG. This accumulation may change with 
cancer treatment, as normal tissues are expected to respond to both radiotherapy and 
chemotherapy. 
This project included 22 patients with advanced-stage non-small cell lung cancer, participating in 
a phase II trial on combined radiation and erlotinib (Tarceva)-therapy. The patients underwent 
three PET-CT examinations; at pre-therapy (prior to radiotherapy), mid-therapy, and post-
therapy (six weeks after therapy). In addition, the patients underwent a complete CT-based 
digital radiotherapy planning. For each patient, the tumor, lymph nodes, lung, heart, esophagus, 
and bone marrow were delineated in the planning CT. The FDG-uptake distribution, in terms of 
the standardized uptake value (SUV), was obtained for tumor and organs at risk (OAR’s) from 
all PET-CT examinations.  
The maximum of the SUV distribution was used to monitor tumor’s response to treatment. The 
median of the SUV was used to monitor treatment induced changes in the OAR’s. Then, Mann-
Whitney’s U-test was employed to compare groups of data. We also tried to identify any 
correlation between OARs’ SUV and radiation dose at mid-therapy and post-therapy. Linear 
regression was used to extract trends. We also investigated the effect of the Tarceva drug by 
separating into a Tarceva receiving group and a non-Tarceva receiving group. A further 
refinement was that we investigated the correlation between density changes in the lung, 
obtained from CT, and dose. 
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A significant (      ) decrease in the maximal tumor metabolic activity was observed from 
pre-therapy to post-therapy session. No significant changes were found in SUV between sessions 
in OAR’s. Also, by looking at tumors and OAR’s, no significant differences were found between 
the Tarceva receiving group and the non-Tarceva receiving group in each session.  
Linear relationships were identified between SUV and radiation dose in both mid- and post-
therapy sessions based on mean FDG uptake in given dose bins. The correlation was positive for 
lung and esophagus and was negative for bone marrow in both sessions. However, for heart a 
positive correlation was identified followed by a negative correlation from mid- to post-therapy 
sessions. A positive linear relationship was also observed between lung density and radiation 
dose. The effect of Tarceva on the FDG uptake in the lungs was significant in both sessions.  
Overall, the results of this study lead us to the conclusion that 
18
F-FDG PET-CT may identify 
changes in tumor glucose metabolism six weeks after radiotherapy. FDG uptake responses were 
also seen in normal tissue with respect to dose. 
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1. Introduction 
Cancer refers to a group of diseases characterized by uncontrolled growth and spread of mutated 
cells. If the spread is not controlled, it can result in death of the host. Cancer is caused by both 
external factors (such as tobacco, infectious organisms, chemicals, and radiation) and internal 
factors (such as inherited mutations, hormones, immune conditions, and novel mutations). 
Cancer treatment includes surgery, radiotherapy, chemotherapy, hormone therapy, and targeted 
therapy.  
Cancer treatment has improved significantly over the past decade. Up to this point, many cancer 
types have become chronic diseases rather than terminal illnesses. This significant achievement 
owes to, among many factors, the effective means of radiotherapy and chemotherapy. Despite 
improvements in radiotherapy and chemotherapy, the outcome of patients suffering from a 
number of cancer types such as lung cancer remains quite poor. Lung cancer is the most fatal 
cancer worldwide (1). In Norway 2902 patients were diagnosed in 2012. Lung cancer is mostly 
diagnosed after presentation of clinical symptoms of the patient. Non-small cell lung cancer 
(NSCLC) accounts for about 80% of the lung cancer cases. It is an aggressive form of cancer and 
patients with NSCLC usually diagnosed with advanced disease (stage III- IV). Only minor gains 
have been made over the past decade in the treatment of advanced non-small cell lung cancer for 
patients in terms of prolonging survival and improving quality of life (2). 
Radiotherapy uses ionizing radiation and delivers prescribed amounts of radiation to the 
malignant tumor usually over the multiple fractions. Radiation is a way of carrying energy in the 
form of particles or electromagnetic waves such as x-rays or gamma-rays. Ionizations occur 
when cells are exposed to ionizing radiation. Radiation kills or controls cancer cells, but can also 
damage the healthy cells in the area being irradiated. Radiotherapy is a common treatment for 
various cancer types such as NSCLC. It is sometimes combined with other treatments such as 
targeted therapy. 
Targeted therapies are developed to block cellular pathways involved in cancer cell survival, 
proliferation, and metastasis. Gefitinib and Erlotinib (Tarceva) have been demonstrated to be 
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effective in front-line therapy in patients with inoperable NSCLC harboring epidermal growth 
factor receptor (EGFR) activating mutations (3). Tarceva is recommended after failure of 
previous chemotherapy and as a maintenance therapy for patients with progressive disease (4) 
(5).   
Imaging plays an important role within the field of medicine and oncology. The ability to 
visualize changes occurring in the body helps physicians to make a better diagnostics and to 
perform a better treatment. Advances in computed tomography (CT) and positron emission 
tomography (PET) have contributed significantly to medical imaging. These contributions were 
not possible without fully exploiting the diagnostic information provided by PET-CT, which in 
turn requires a deep knowledge of both PET and CT. CT is an imaging modality which measures 
x-ray attenuation within the bodily tissues while PET uses radiotracers to observe specific 
physiological processes such as glucose uptake. PET was realized in the 1970’s by Phelps and 
colleagues and became clinically available in the 1990’s (6). 
18
F-fluorodeoxyglucose (FDG) PET-CT has become part of the standard protocol in the 
diagnosis, staging, and therapy response assessment for various types of cancers (7). It is well 
known that there is an increased transport of glucose into malignant cells and up-regulation of 
enzymatic activity which results in an increased tracer uptake. FDG uptake is not specific to 
cancer. Benign and inflammatory disorders have also been reported to take up FDG. Combined 
PET-CT is therefore essential in order to separate normal physiologic uptake from pathologic 
uptake. In other words, PET-CT provides us with accurate localization of functional 
abnormalities in the body. Furthermore, PET-CT scans before, during, and after treatment helps 
us to evaluate treatment by assessing the FDG uptake changes in the tumor as treatment 
progresses. It may also help us evaluate normal tissues response during and after the treatment. 
This study evaluates FDG uptake and tissue density within the tumor and various organs at risk 
in 22 patients with NSCLC who have received fractionated radiotherapy. These patients have 
undergone three 
18
F-FDG PET-CT examinations; prior to radiotherapy, at mid therapy (after 
typically 15 Gy), and six weeks after therapy. The major scientific goals of this study are: 
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Can 
18
F-FDG PET-CT be used to detect metabolic changes in the tumor and normal tissues 
following radiotherapy? Can we identify any correlations or trends between glucose uptake in 
normal tissues and local dose? Can CT scans be used to assess changes in the lung density? Can 
we identify any trends between lung density and local dose? Is
 18
F-FDG PET-CT a suitable 
biomarker in order to monitor Tarceva treatment over time? In order to answer these questions 
the first step would be to develop a computer program for reading and displaying PET and CT 
images of various organs and tumor and also to co-register the planning CT, dose, and a series of 
PET-CT images. 
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2. Background 
2.1. Cancer 
Malignancy arises from changes in cell regulation and tissue growth. To understand the process, 
it is important to appreciate the normal mechanisms by which growth is controlled in human 
tissues.  Pathways are controlled in a way that cells are replaced or repaired with an appropriate 
rate and without altering the normal balance of different types of cells in a tissue. In other words, 
there is interplay between growth stimulants and suppressors in cells. 
Damages to DNA can occur every day in the life of a cell. These may have different causes, such 
as infections, viruses, genetic instability, and chemical agents. However, in most cases damage 
will be repaired before it proceed to further changes or mutations. Cancer may be initiated when 
DNA damage occurs in an important part of the DNA sequence and left unrepaired. In such 
cases multiple subsequent changes in the DNA lead to failure in response to normal regulatory 
system, either an excess in growth factors or lack of the tumor suppressors. As a result, a 
transformed cell will be produced which will proliferate excessively until a potentially malignant 
clone of cells is produced. These progressive changes accumulate in the genome and make this 
progression irreversible. 
2.1.1. Lung cancer  
Lung cancer is described by the excessive growth of malignant cells in one or both lungs. It can 
start in the cells lining the bronchi, bronchioles, and alveoli (Figure 56). Changes in the lung 
cells’ DNA can make them grow faster. In this phase of the disease, cells do not form a mass; yet 
it is not possible to see any abnormalities—for instance from chest x-ray. Overtime, these cells 
may have further mutations and become cancerous. Formation of new blood vessels from pre-
existing vessels (angiogenesis) provides cancerous cells with nutritions and oxygen. This results 
in formation of a tumor that can be observed by medical imaging modalities. 
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Lung cancer is categorized by how cancerous cells look like under microscope. The two main 
types of the lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC). The prognosis of lung cancer is poor because the lungs are large and tumors can grow 
in them for a long time before they are found. Some symptoms, such as coughing and fatigue, are 
usually mistaken by people as being caused by other means. For this reason, early-stage lung 
cancer (stages I and II)
1
 is difficult to detect. Most people with lung cancer are diagnosed at 
stages III and IV.
2
 In this aggressive disease, blood-borne metastasis can occur to all sites of the 
body, especially in the bone, liver and central nervous system (CNS). 
Lung cancer is the leading cause of cancer death for both men and women in the world. The 
incidence of lung cancer in Norway was about 2902 in 2012 (1602 in men and 1300 in women) 
(8). The number of deaths from this disease is similar in number to the incidence, reflecting the 
poor prognosis. 
It is clear that smoking is the primary risk factor for lung cancer and accounts for more than 85% 
of all lung cancer-related deaths. The occurrence of lung cancer is correlated to the number of 
cigarettes smoked per day and the number of years spent smoking. Second-hand smoke is also 
known as a cause of developing lung cancer. Exposure to radon gas
3
 also increases the risk for 
lung cancer. Other, less probable, causes have also been identified. 
2.1.2. Non-Small Cell Lung Cancer 
About 80% to 90% of lung cancers are non-small cell lung cancers. Among them are three sub-
groups called Adenocarcinoma, Squamous cell carcinoma, and Large cell carcinomas. These 
                                                 
1
 Stage I: The cancer is located only in the lungs and has not spread to any lymph nodes. 
Stage II: The cancer is in the lung and nearby lymph nodes. 
2
 Stage III: Cancer is found in the lung and in the lymph nodes in the middle of the chest. 
Stage IV: This is the most advanced stage of lung cancer, when the cancer has spread to both lungs, to fluid in the 
area around the lungs, or to another part of the body, such as the liver or other organs. 
 
3
 Radon is a radioactive gas that is produced by the decay of radium 226. 
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cells differ in size, shape, and genetic make-up. However, the prognosis and treatment of such 
tumors are very similar. Surgery can be curative when the disease is localized, but most of the 
newly diagnosed patients have their disease widely spread and thus palliative treatment is the 
only option for such patients. 
In order to deliver an appropriate treatment to the patient diagnosed with lung cancer, the doctor 
must determine the type and stage of cancer. This can be done by examining the lung tissue with, 
for example, biopsy. Biopsy is a way to remove a small piece of tissue for examination under a 
microscope. Other tests such as computed tomography and positron emission tomography may 
be performed in order to optimize the treatment and see how effective an ongoing treatment is 
during and after treatment. 
2.2. Computed Tomography (CT) 
A Computed Tomography (CT) combines computer and x-ray technology to produce 3 
dimensional images of internal organs. CT scanner consists of a rotating x-ray tube and detectors 
on opposite sides of the patient to acquire cross-sectional images. CT is based on a measurement 
of x-ray attenuation through a desired section. CT scanners originate back in 1895 and 
exploration of x-rays by Wilhelm Conrad Röntgen. Modern CT scanners have a stationary or 
rotating detector array with a fan beam x-ray tube which is rotating around patient.  
In helical (spiral) CT scanners which are widely used, the patient’s table moves continuously 
while the x-ray tube acquires a series of projection images (Figure 1). A slice of the CT image is 
composed of voxels (volume elements). The numeric value in each voxel represents physical 
property of the tissue, called x-ray attenuation, or tissue density. These numbers are called 
Hounsfield units or CT numbers. The linear attenuation values normalized to the attenuation of 
water. This normalization is given by following equation: 
water
waterxHU

 
1000  
Here,    is the linear attenuation coefficients of tissue x and         is the linear attenuation 
coefficients of water. 
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Figure 1: Spiral CT scan demonstration. 
CT number gives an indication of the type of tissue. Water has a CT number of zero. Negative 
CT numbers are typical for air spaces, lung tissues and fat tissue (Figure 2). Radiologists 
occasionally make critical diagnostic decisions based on CT number of particular regions of 
interest. 
 
Figure 2: The Hounsfield scale of CT numbers (9). 
Rotating x-ray 
source 
Motorized 
table 
Rotating x-ray 
detectors 
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2.3. Positron Emission Tomography (PET) 
PET scan is an important and valuable modality in radiotherapy. This imaging tool is growing 
faster than any other imaging modalities, and oncology is by far the most common field of 
application (10).   
 PET is a functional imaging technique that uses positron labelled tracers to produce three-
dimensional, color images of the metabolic activities within the human body. The process is as 
follows: first, a radioactive tracer is injected and then gamma rays that are emitted from the 
patient’s body are detected with a camera. PET tracers are usually a positron-emitting 
radionuclides placed on a biologically active molecule. Reconstructed PET images, along with 
CT images, give nuclear medicine specialists structural and functional information of the organs. 
In the next paragraphs we will talk in more detail about radionuclide and basic physics of the 
positron interactions as they play an important role in PET scan.  
2.3.1. Radionuclide and positron decay 
A positron emitter is a radioactive atom, or radionuclide, with an excess number of protons 
which may decay through the emission of positron. In positron decay an excess proton from a 
radionuclide is converted into a neutrino and a positron
4
. Positron decay is shown in the equation 
below: 
  eYX
A
Z
A
Z 1  
Here, X is the original radionuclide of mass number A and atomic number Z, Y is the daughter 
nuclide, e
+
 is the positron, and   is a neutrino. Neutrinos that are produced in positron decay 
rarely interact in tissue and are almost impossible to detect. However, they influence the energy 
and range of the positrons, and as a result, the positron can have a spectrum of kinetic energies 
from zero up to a maximum value (Emax). The distance the positron travels in matter is 
determined by its kinetic energy. 
                                                 
4
 A positron has the same mass as an electron but has a positive electric charge. 
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2.3.2. Positron annihilation and PET 
Because positron has a very short range in tissue (a few millimeters); it cannot escape from the 
body. Instead it slows down through multiple collisions with atomic electrons and then combines 
with an electron to form a positronium
5
. The short-live positronium annihilates to produce two 
photons with the same energy of 511 keV, which are emitted back-to-back in opposite directions 
according to the following equation: 
  ee-  
These two photons ( ) must escape the patient’s body and then be detected simultaneously in 
two of the PET detectors. 
A PET camera contains several rings of detectors (usually made of scintillation crystals) which 
are coupled with photo multiplier tubes
6
 (PMTs). Whenever two opposed detectors receive two 
photons with a right energy (around 511 KeV) and within a temporal proximity (few 
nanoseconds), they’d likely came from the same annihilation. These two photons are recorded by 
the PET computer system as a “coincidence.’’ Annihilation occurs on the line between each 
coincidence event (Figure 3). 
                                                 
5
 An unstable exotic atom contains an electron and a positron. 
6
 Where photons are converted into an electrical signal to be later processed into an image 
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Figure 3:  Schematics for a PET acquisition process (11). 
An event line records the approximate position of an entry. The lines are then summed up to 
make a representation of the activity. Because summing up the lines is in fact an averaging 
operation, the resulting picture would be vague or blurry. In order to improve the picture, a 
sharpening filter is applied through the process of “filtered back projection.” All data is stored in 
a three-dimensional matrix where each element of the matrix is a cube called a “voxel.” A voxel 
is the smallest element of visualization and represents the average of measurements taken at a 
point in space. 
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2.3.3. Tracer 
A tracer is a molecule labeled by an appropriate positron emitter isotope and is usually 
introduced to the patient’s body through a vein before image acquisition. This molecule should 
be of a type that is easily taken up by the cells in a given organ or by a pathological condition. 
The preferred radionuclides (Table 1) in PET imaging are those that decay primarily by positron 
emission and not by electron capture
7
 (i.e. that have a high atomic number). These nuclides 
should also have suitable half-lives. Radionuclides can be artificially produced in a cyclotron and 
be employed for making a PET tracer. 
Table 1: lists the properties of radionuclides that are commonly used in positron emission 
tomography. 
Nuclide Half-life (min) E max(MeV) β
+ fraction Positron range in water (mm) 
11C 20.4 0.96 1.00 3.9 
13N 9.97 1.19 1.00 5.1 
15O 2.1 1.73 1.00 8.0 
18F 109.8 0.63 0.97 2.3 
64Cu 762 0.65 0.29 2.3 
68Ga 67.8 1.89 0.89 9.0 
82Rb 1.27 2.60 0.97 18.0 
122I 3.6 1.09 0.77 7.4 
 
Currently, 
18
F- fluorodeoxyglucose [
18
FDG] is the most widely used tracer in nuclear medicine. 
By removing second hydroxyl group from glucose and replacing it with 18-Flourine isotope, 
                                                 
7
 When a proton rich nuclide captures its own electron, the electron combined with a proton and creates a new 
neutron. The atomic number goes down by one.  
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18
FDG is produced (Figure 4). The half-life of 
18
F (109.8 min; Table 1) is long enough that it 
makes it possible to be employed efficiently, while at the same time it is short enough not to 
expose the patient and the surroundings to excessive amounts of radiation after the examination.  
 
Figure 4: left: Chemical structure of D-glucose monohydrate, right: Chemical structure of 
18
FDG. 
Glucose is one of the primary sources of energy for cells. It is distributed through the blood and 
the cellular uptake is regulated by insulin. Molecular weight of FDG is quite close to that of the 
glucose molecule. This implies that FDG is actively accumulated in most tissues and tumors. The 
glucose transport mechanism carries the FDG into the intracellular environment where it 
undergoes enzymatic phosphorylation. Once FDG is phosphorylized, it cannot be further 
metabolized and is trapped within the cell. Therefore, FDG uptake, as reflected in 
18
FDG-PET 
images, is a good indication of glucose uptake distribution in the cells and can be marker of the 
degree of anaerobic glucose metabolism. Hence, FDG is useful to identify and characterize 
tumors.  
However, not all tissues with elevated rates of glucose uptake are indicative of malignancy. The 
FDG-PET scan may also reveal uptake in normal, healthy tissues. For instance, the brain, even at 
rest, is the dominant site of glucose utilization. Also the heart, particularly the left ventricle, is 
always in need of energy. Adenomas, fibroids, and inflammatory tissues also have shown intense 
uptake on FDG-PET scan. Furthermore, the inflammatory response to therapy, either radiation 
therapy or chemotherapy, will be associated with increased FDG accumulation. 
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2.4. PET-CT 
PET scan is a functional imaging technique and the anatomical information of such a scan is 
limited. In order to get useful data, combination of PET scan with a structural imaging such as 
CT scan plays an important role in medical imaging. Almost all PET scanners today are 
combined with a Computed Tomography (CT) scanner so that the PET images can be fused with 
the CT images. As mentioned earlier, CT reflects the x-ray attenuation properties in tissue, and is 
often used as a proxy for tissue density. It reflects the patient anatomy, and is useful for 
identifying different tissues such as the heart, lungs, muscle, and fat. This information is not 
reflected in PET images, and so it is common to combine the two in PET-CT scans (Figure 5). 
This combination provides adequate anatomical detail to improve the anatomic placement of 
observations and accuracy of the test. 
 
Figure 5: A PET-CT system (12). 
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2.5. Standardized Uptake Value (SUV) 
18
F-FDG PET-CT makes it possible to study the metabolic and anatomic response to therapy in a 
given patient. Changes in tumor tissue uptake of FDG are frequently reported as change in 
“SUVmax”. SUV is a semi quantitative value that is independent of patient’s size and amount of 
FDG administered before examination. Although there is some source of bias and variance in 
estimating of FDG uptake, SUV is still most commonly used in FDG-PET imaging and is 
mathematically derived from the following formula: 
     
                            [
  
  ⁄ ]           [  ]
                  [  ]
 
Activities in the body that cause changes in glucose metabolism can affect the SUV and make 
the scan interpretations even more complex. 
2.6. Radiotherapy 
Radiotherapy or radiation therapy generally refers to cancer treatment with high energy particles 
or electromagnetic waves. Ionizing radiation such as x-rays traverses through the cells of an 
organ, causing DNA damage. As cancer cells often have less efficient DNA repair, fractionated 
radiotherapy may give a higher cellular effect in tumor compared to normal tissue. Linear 
accelerator or Linac (Figure 6) is a device mostly used for external beam radiation therapy. 
Linacs are based on the acceleration of electrons using strong microwaves and can provide x-
rays at various megavoltage energies. The produced x-ray beams may range from 4 to 25 MeV, 
and can penetrate more or less all parts of the body. 
15 
 
 
Figure 6: An illustration of Linac system.  
Radiotherapy is classified into three branches: curative, adjuvant, and palliative radiotherapy. 
Curative radiotherapy is prescribed by a radiation oncologist for those patients who have a 
localized tumor. Sometimes radiotherapy can be used as an adjuvant therapy to other treatments 
like surgery to ensure sterilization of the residual tumor or tumor bed. For patients with very 
advanced disease, e.g. with metastasis (distant spread), radiotherapy can be employed as a 
palliative therapy.  
The aim of palliative radiotherapy is to relieve pain and improve the quality of life in patients 
with a limited survival time. Treatment is rather simple using a single or two opposed treatment 
beams and is done over a short period of time. Lower doses (compared to curative and adjuvant 
radiotherapy) are given to patients who received palliative care in order to minimize the side 
effects. 
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When the total dose is given to the patient in fractions over a period of time, it is called 
fractionated radiotherapy. Fractionated radiotherapy is beneficial in some aspects, for example it 
gives to normal tissue time to repair, and it also lets tumor cells move on to a more sensitive 
phase of the cell cycle. 
2.7. Unwanted Side-Effects of Radiation 
It is almost impossible to treat cancer using radiation without exposing healthy tissues. In other 
words, damage to the normal tissues, especially to those that are close to the tumor, is inevitable. 
The mammalian tissues respond to radiation in forms of cell death and cell damage together with 
repair capacity. While the severity of radiation-induced damage in a tissue depends on the RT 
dose, the onset of damage mostly depends on cell kinetics of the tissue. Tissue’s ability to 
repopulate after irradiation is one of the most important factors in order to determine radiation-
induced normal tissue injury. In 1906 Bergonié and Tribondeau reported that the sensitivity of a 
tissue to radiation is related to its mitotic activity, and decreases with cells’ degree of 
differentiation [cited in (13)]. Non-dividing differentiated cells, such as the ones that build up 
muscle and lungs, are classified as radio-resistant and relatively unaffected by radiation and 
continue to function and die at their normal rate. In contrast, bone marrow cells which rapidly 
proliferate are categorized as radiosensitive cells. 
Although radiotherapy represents a good approach to treat a cancer patient, radiation induced 
toxicity needs to be considered. Such toxicities range from early to late effects and depend on the 
treatment and organs being treated. Early effects of radiation may be seen a few days or weeks 
after treatments have started and may go on for several weeks after treatments have ended. Other 
effects may not show up until months, or even years, later. 
2.8. Tarceva or Erlotinib 
As we previously discussed cancer originates from a malignant cellular transformation, leading 
to uninhibited cell growth. Overexpression of Epidermal Growth Factor Receptors (EGFR’s), 
which allow cells to divide and grow uncontrollably, have been found in many cancer types such 
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as lung cancer
8
. Some studies have shown that certain types of drugs, like tyrosine kinase 
inhibitors (TKIs), can help treat these kinds of cancers. 
The use of TKIs belongs to a new class of treatments called targeted therapy. Generally, targeted 
therapy targets specific genes prevent cancerous cells from growing. TKIs block EGFR from 
working, resulting in a stop or slowing down tumor growth. The drug Tarceva (Figure 7) is an 
EGFR inhibitor. A series of trials have shown that Tarceva improves the survival of patients with 
advanced incurable NSCLC who have failed standard therapy (14). Therefore, Tarceva is an 
approved medication therapy in lung cancer. 
 
Figure 7: Tarceva chemical structure (15). 
 
 
The material in this chapter was also adapted from (16) (17) (18). 
                                                 
8
EGFR testing helps us move toward our goal of tailoring treatments for the patient. 
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3. Material and Methods 
3.1. 18F-FDG PET-CT scanning and data preprocessing  
3.1.1. Acquisition 
This project includes 22 patients with advanced non-small cell lung cancer who have received 
fractionated palliative radiotherapy (310 Gy) at Oslo University Hospital. The patients have 
been recruited into the ThoRaT (Thoracal Radiotherapy and Tarceva) study, which has been 
approved by the regional committee for health ethics and is currently running. A written 
informed consent was obtained from all patients. The current study, which focuses on data 
analysis, has no consequence for the patients whatsoever. The patients included have undergone 
at most three 
18
F-FDG PET-CT examinations using a Biograph 16-scanner (Siemens, Germany); 
one prior to radiotherapy, one at mid therapy (after typically 15 Gy), and one six weeks after 
therapy. 
Thirteen of these patients who have undergone thoracal radiotherapy also received oral Tarceva
9
, 
once every day, from the day before start of radiotherapy. Nine of the 13 patients finished with 
the Tarceva in the last day of radiotherapy and the remaining 4 patients had Tarceva maintenance 
treatment until disease progression. 
Before the treatment started, patients underwent a pre-treatment CT scan (CT simulation) using a 
light speed ultra-scanner (GE medical systems, USA). The CT image series is then sent to a 
radiotherapy planning program, in this case Oncentra Planning (Oncentra ® External Beam, 
Elekta, Sweden). Here, the treatment is planned on the basis of the tumor location and anatomy 
of the given patient, as reflected in the CT images. Treatment plan include two opposed 6 MV 
photon beams and the fractionation is 3 Gy  10. For the purpose of the current study, the 
planning CT is used to delineate various parts of the thoracic area such as Gross Tumor Volume 
                                                 
9
  150 mg p.o. (independent of the patient’s body surface) 
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(GTV), lymph nodes, Ipsilateral Lung (IL), Contralateral Lung (CL), heart, bone marrow, and 
esophagus. 
In oncology, a routine 
18
FDG-PET acquisition protocol consists of several steps. Since tumor 
uptake of FDG is not insulin dependent, FDG-PET imaging is augmented in the fasting state. 
Blood glucose is lower in fast patients and the image is less contaminated with muscle activities. 
In this regard, patients should not eat and drink liquid containing fat or sugar (for instance milk) 
at least six hours prior to the examination. An appropriate hydration is required for FDG 
secretion and patients are told to drink water before examination is performed.  
Blood glucose level should be determined prior to FDG administration. If blood glucose is too 
high
10
 the quantitative measurements are not considered valid and depending on this level the 
examination could be postponed. Tracer is administered at least one hour before data acquisition 
and patients are examined with CT scan followed by PET scan. The amount of FDG may vary 
from scanner to scanner, at the Radiumhospital, adults receive approximately 400 MBq. 
After injection of FDG, patients should avoid excess movement and exercises both mentally and 
physically. She/he has to lie down in a quiet room and relax. Also, it is important that the patient 
feel warm and comfortable. All these precautions are to avoid unspecific FDG uptake in the 
muscles and brown fat. 
3.1.2. PET-CT images 
In this project, PET and CT images are acquired in the same scanner and are produced in the 
DICOM
11
 (Digital Imaging and Communications in Medicine) file format. The images can be 
displayed and further analyzed with the help of Interactive Data Language (IDL).  
A DICOM file consists of image and also patient and image data which are placed in the header. 
The DICOM header consists of different variables that are extracted from the data object and can 
                                                 
10
 Fasting blood glucose range is between 5.1-6.8 mMol/L. 
11
 A standard for file exchange in medical imaging developed by NEMA, National Electrical Manufacturers Associ-
ation 
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be read by the program called eFilm DICOM Dump. Two numbers correspond to each of these 
variables and are called hex codes. Some of the important properties of such variables are listed 
in Table 2. 
Table 2: List of Dicom hex codes. The two leftmost columns are the identification tag. The Dicom 
value is the value returned by the IDLffDICOM object when the GetValue (hex1, hex2) is called. 
Hex codes Dicom value 
0028 0010 Rows 
0028 0011 Columns 
0028 0030 Pixel spacing 
0018 0050 Slice thickness 
0028 1053 Rescale slope 
0020 0032 Image position 
0018 1072 Radionuclide start time 
0018 1074 Radionuclide total dose 
0020 0013 Instance number 
0008 0032 Acquisition time 
07FE 0010 Pixel data 
0028 1053 Rescale slope 
3004 000E Dose grid scaling 
 
3.2. IDL 
Interactive data language is platform independent, array-oriented program for scientists and can 
be used in the analysis and visualization of multi-dimensional data sets. It has grown out of 
programs written for analysis of various NASA mission’s data such as Mariner. IDL is a 
computing environment which can help visualize and analyze any modality of medical imaging. 
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This program has extensive coding rules and syntax. In the current project, one of the main tasks 
was to create a program in IDL that can read DICOM files and co-register different image 
modalities. 
3.2.1. Reading medical imaging data 
In order to open and read arbitrary DICOM files from the specified disk file, IDLffDICOM must 
be used. IDLffDICOM object is one of the several file reader classes that contains the data of the 
image embedded in a DICOM file and can only read DICOM tags. Below are example code 
lines: 
obj= OBJ_NEW('IDLffDICOM') 
files= FILE_SEARCH ('*', count= nct) 
read=obj->Read(files(0)) 
dim_x=obj->GETVALUE('0028'x, '0011'x,/NO_COPY) 
The OBJ_NEW allocates the memory needed to store the data read from the file. The 
GETVALUE function uses appropriate set of hex numbers that belong to desired variable. The ‘x’ 
after these two numbers implied that they should be read as hex values. 
The FILE_SEARCH function returns a string array containing the names of all files matching the 
input path directory. The returned array contains pointers to all elements in the object. This 
function returns    if no matching element is found. The keyword No_copy is used when we 
want the pointers returned point to the actual data (not copied data) in the object for the specified 
DICOM tags. 
Columns and rows give the number of pixels, or matrix size, in x and y direction. For example in 
this project, number of pixels in the CT images is 512×512 and in the PET images is 168×168. 
The number of image slices (in the z direction) is equal in both image series, but can vary 
between patients. The slice thickness is 5mm for both CT and PET images, while the difference 
between the two consecutive z-positions is 3 mm. This implies that there is an overlap between 
the two consecutive slices. Z-position together with x and y position can be found in image 
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position variable. Image position is such a variable stored in the DICOM header as a string point 
array. In order to get the floating point array the STRSPLIT function were used (following lines) 
which splits image position string argument into separate substrings. The FLOAT function then 
converts substrings into a single-precision floating-point value.  
ct_pos=obj->GETVALUE('0020'x, '0032'x,/NO_COPY) 
ct_pos=*ct_pos(0) 
ct_pos = FLOAT(STRSPLIT(ct_pos,'\', /EXTRACT ) ) 
3.2.2. Displaying medical imaging data 
After reading the desired data in IDL, the next step is to visualize image data. There are several 
methods to perform this task. The most commonly used methods for displaying static medical 
images is “direct graphics”. This method provides with number of commands12 for quickly 
displaying images which are stored as two dimensional arrays in IDL. Medical images separate 
into gray scale and RGB. Gray scale images are represented by a two dimensional array of 
numbers which are proportional to pixel intensity or brightness. On the other hand, in three 
dimensional RGB images, each pixel is labeled with mix of three colors, red, green, and blue 
which represent the resulting color of the certain pixel. 
To evaluate the right SUVs for different delineated organs of our interest in thoracic area, we 
need to first be sure that all images are precisely overlaid. This has been done in several steps 
that will be discussed in the following paragraphs. However, before introducing co-registration 
of the images, some corrections must be done in order to get a right data value for PET, CT, and 
dose images.  
In PET image decay correction is needed before convert image data to SUV map. The decay 
constant   is equal to
2/1
2ln
t
 ; which 2/1t  is the half-life of the radioactive material (i.e. 
109.771 for FDG). The decay correction, A, is then derived by the equation below: 
                                                 
12
 Such as TVSCL, TV, etc. 
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)].(exp[ 01 ttA    
Where    is the radionuclide’s start-time and 1t  is acquisition time and they were extracted from 
the PET images’ header and converted to decimal system before they used in decay correction. 
Radionuclide activity, rescale slope, and patient’s body weight13 are the other parameters that 
need to be considered in SUV calculation. Rescale slope is a conversion factor to map the values 
stored in the data array to the actual units in MBq/ml in PET. 
Pixel value in CT image represents mean attenuation of the tissue, ranging between 0 and 4000. 
In order to get a Hounsfield Unit (HU) from image data the following linear transformation is 
applied: 
                                                    
Both rescale slope and rescale intercept can be found in DICOM header and are equal to   and 
      respectively. Accordingly, the HU range is from       to      or more. 
The third consideration that we need to take into account is how to manipulate RT dose image in 
order to get the right dose response for different organs. The RT Dose module is used to convey 
3D array of radiation dose data generated from treatment planning systems and gives us the 
information about amount of dose received in various parts of irradiated tissues. In the current 
study the attributes defined within the module support dose for single beam comprising a 
complete treatment plan. In order to get the whole dose over thoracic area we summed two 
opposed beams. It is important to multiply each dose frame by dose grid scaling before 
summation. Pixel value in RT dose image is a relative dose to an implicit reference point and is 
not in Gray units. Dose grid scaling value is a factor for converting dose data from pixel value to 
Gray. 
                                                 
13
 In this project, patient’s weights are lost in the header after the patients’ identities are removed. We entered this 
data into the program manually.  
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3.2.3. Co-Registration of images 
Accurate alignment between CT and PET images is vital especially when it comes to analysis 
glucose uptake value of GTV and organ at risk. This is done by visualizing both CT and PET 
images simultaneously in the same window and applying an appropriate program to minimize 
the misalignment. The best parts to consider if these images are aligned or not are bone and rib 
cage. CT and PET images from each session were not always overlaid precisely. In order to 
remove a shift that causes this problem, one can calculate the shift in x and y directions
14
 (code 
line below) and apply it on the PET image. 
diff=[round((pt_pos(0)-ct_pos(0))/ref_res(0)),round((pt_pos(1)-ct_pos(1))/ref_res(1))] 
Pt_pos are positions of PET image and ct_pos are positions of CT image, index 0 and 1 
correspond to x and y direction respectively. This adjustment was minimal since each 
18
F-FDG 
PET-CT scans was done in the same machine and may affect only the borders. 
PET and CT images have different resolutions. PET scan usually has a poorer resolution 
compared to CT scan. In PET-CT fusion display, PET slice interpolated to the same resolution as 
the CT to get a smooth image. Image fusion for all the patients in three different slices; 
transversal, sagittal, and coronal had been checked to validate the IDL program that is made in 
this respect (Figure 8-A). 
Since radiotherapy treatment planning was made based on planning CT, co-registration of 
planning CT image and RT Dose image had been done by employing an appropriate positional 
shift. Validation of this co-registration was acquired with the help of fused planning CT image 
and RT Dose image for all of the patients (Figure 8-B). 
                                                 
14
 There is no need to shift PET in z-direction because all CT and PET images are sorted. 
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Figure 8: A transversal slice chosen from patient 3 at mid-therapy session. A: Co-registered 
PET-CT is demonstrated. B: Co-registered planning CT and radiotherapy dose distribution is 
demonstrated. 
Up to now all PET-CT scans and planning CT-RT dose are co-registered. Since all the 
radiologist’s delineations have been done based on the planning CT, all  available sets of PET-
CT images need to be co-registered with planning CT. Considering that CT and planning CT 
scans are acquired in a different machine, they don’t have the same reference coordinate and 
hence FOV (Field Of View) is different for these two images. In order to deal with this 
registration, the IDL codes in this subroutine search for the maximum correlation between each 
sets of CT image and planning CT image and the calculated shift in x, y, and z directions is then 
applied on CT sets (Figure 9). Once each sets of CT image co-registered with planning CT 
image, we can use the same shift on PET sets to have planning CT and PET sets co-registered. 
All the excess data, out of the thoracic area, in PET-CT scans was cut-off with the help of the 
calculated shift in the z-direction.  
In this part of the program when correlation was applied, we encountered a memory problem; 
because arrays were too big. In order to deal with memory problem and also get unify resolution 
for all the images, we introduced a reference resolution (ref_res) and interpolated all the 
A  B 
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resolutions to this resolution. From now on all of the images (PET-CT, planning CT and RT dose 
images) have 3mm resolution in x, y, and direction. 
 
Figure 9: A transversal slice chosen from patient 3. A: CT image from mid-therapy session, B: 
Planning CT image, C: Un-shifted CT and planning CT, D: Co-registered CT and planning CT. 
After this final adjustment, all the images were overlaid precisely on the planning CT. The 
delineations from the planning CT can be used to extract desired data from different PET-CT 
sessions to see how these data change, for example, with dose value and time. The following 
images were registered PET images from different sessions on planning CT image (Figure 10). 
Data from these registrations together with contours in planning CT provide us with useful 
A B 
C 
D 
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standard uptake value in various organs and how the SUV of such organs change with time and 
dose. 
 
Figure 10: Co-registered planning CT and PET scans of patient 6 at different time points. The 
left column corresponds to prior to treatment, the middle to mid-treatment and the right to post-
treatment. The upper, middle, and lower images correspond to the coronal, sagittal, and axial 
plane, respectively. 
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In this phase of the project, different contours were used as an index both on CT and PET data to 
extract SUV and CT number belonging to these contours (Figure 11). Because there is usually 
some error on registration of images and in order to be sure that glucose uptake in GTV and 
lymph nodes does not affect the other organs of interest, dilate command was applied on GTV 
and lymph nodes delineation to make a margin around it and then to use this new object carved 
out of other organs. In addition, for lungs, margined contour of heart, esophagus, and bone 
marrow had been carved out. Also we used a CT number window between value of 100 and 800 
for lung in all CT sessions in order to make sure that all of the voxels included in the lungs are 
indeed lungs. 
 
Figure 11: Illustration of various delineations, laid over mid-therapy PET scan slices from 
patient 1 
     GTV      Lymph node                 Heart  
 Bone marrow       Contralateral lung   Esophagus 
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3.3. Data analysis  
The SUVs of various organs which are stored in voxels and come in 3D matrix can be presented 
in histograms. In this study, the histogram refers to a graph that is generated from the number of 
voxels in an image containing values of a specified intensity range. The signal intensity may be 
expressed as Becquerel’s per voxel or as a Standardized Uptake Value. The total value range, the 
maximum value of the data points minus the minimum value of the data points, is divided into 
bins with equal lengths. Larger bins draw a coarse representation and eliminate the noise while 
smaller bins provide higher resolution. For each bin, the voxels in the region of interest that have 
a value within the bin range are counted. This value is then normalized to the total number of 
tumor voxels.  
In order to have an overview of how SUV in different organs change with sessions, it is common 
to reduce SUV of patients to the mean value. Mean includes all data points but gives a 
dependency on the definition of the border and as such introduces inter observer variability. If 
the delineation of organs is done in a strict way less of the surrounding tissue is included and a 
higher mean will be calculated. The value is however robust and rather independent of noise. 
Furthermore, the tumor and lymph nodes could also be represented with their single highest 
value, which is maximum value (SUVmax). This value represents the most active part of the 
tumor or affected lymph nodes. 
Can we identify any changes in SUV of OAR’s with dose? In order to answer this question, first 
total dose was binned to the size of 0.5 Gray in order to have clear trance of SUV. Second, 
SUVmean was calculated over each dose bins and SUV versus dose is plotted (Axis x shows the 
delivered percentage of dose). Example below shows such a plot for ipsilateral lung of patient 4 
in mid-therapy and post-therapy since pre-therapy PET scan is not linked to RT dose (Figure 12). 
The same technique was applied to plot density response versus RT dose in the lung tissue. 
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Figure 12: SUV in the ipsilateral lung versus percentage delivered dose from patient 4. A: at 
mid-therapy, B: at post-therapy session. 
3.4. Box-Whisker plot 
Box-whisker plot is an exploratory graphic and is a helpful way to display the distribution of the 
data.  The box plot displays data broken down into three quartiles, each with an equal number of 
data values. Furthermore, the lines extending vertically from the box are called whiskers, 
showing the variability outside the upper and lower quartiles. The plot also shows where the 
mean of the data lies. Below is a formal description of the statistics:  
Q1 – quartile 1: the median of the lower half of the data set (25th percentile). 
Q2 – quartile 2: the median of the entire data set. 
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Q3 – quartile 3: the median of the upper half of the data set (75th percentile). 
Mean Value: the average value of the entire data set.   
Extreme Values: the smallest and largest values in a data set. 
3.5. Statistical Inference 
3.5.1. Mann-Whitney U-Test 
In order to identify significant difference in glucose uptake level between two sessions, Mann-
Whitney U-test (Also known as the Mann-Whitney-Wilcoxon (MWW) or Wilcoxon Rank-Sum 
Test) was applied. This test is a great substitute for two-sample t-test, since the distributions of 
data in this project are unknown and they do not necessarily come from a normally distributed 
population. On the other hand, Mann-Whitney U-test is suitable for a sample size smaller than 
20. This test is used to test the null hypothesis that two populations have identical distribution 
functions against the alternative hypothesis that the two distribution functions differ only with 
respect to their medians.  
In order to calculate the U statistics, the combined set of data is first arranged in ascending order 
with tied scores receiving a rank equal to the average position of those scores in the ordered 
sequence. If R1 and R2 denote the sum of ranks for the SUV level of patients included in 2 
different sessions for certain organ, The Mann-Whitney test statistic (U) is then calculated using 
the following formulas: 
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Here, N1 and N2 are the sizes of the two samples (sessions). 
32 
 
We next compare the value of calculated U with the value given in the Tables of Critical Values 
(Table 6) for the Mann-Whitney U-test, where the critical values are provided for given N1 and 
N2 , and accordingly accept or reject the null hypothesis (      ). 
Sample size in different sessions was equal to the number of patients examined in pre-therapy, 
mid-therapy, and post-therapy session which was 14, 19, and 7, respectively (patient 12 and 24 
were missing contralateral lung structures, and delineations for heart and esophagus of patient 15 
were not available). 
3.5.2. 95% confidence interval 
SUV levels are measurements of uptake values and are subject to errors of measurement. These 
instrumental and human errors can be considered as a source of noise (with a random nature). 
We assumed SUV levels (relative to dose) in each session were samples taken from the unknown 
variable of “glucose uptake relative to dose.” Then, the two unknown variables are different with 
95% accuracy if their 95% confidence–intervals are completely separate (no joint interval).  
The variables discussed in this work (for example, glucose uptake values for mid-therapy and 
post-therapy) are not directly observable, instead, the results of the measurements of SUVs show 
“samples” taken from these variables. In order to see if the uptake values (relative to dose) in 
mid-therapy and post-therapy are indeed different, we need to perform a statistical significance 
test. A 95% significance test of the difference determines if the difference in two variables is due 
to naturally occurring phenomenon and not contributed to chance alone.  
The same test was used to identify significant differences between Tarceva receiving patients 
and non-Tarceva receiving patients at mid-therapy and post-therapy session. 
 
 
The material in this chapter was also adapted from (19) (20) (21). 
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4. Results and analysis 
4.1. Visual inspection 
In this study, morphological changes in normal lung tissue and tumor tissue varied between 
patients. In Figure 13  and Figure 14, there are two extreme examples of patients with respect to 
anatomical changes during the examination period. These changes are presented from the 
planning CT acquisition to the last session of 
18
F-FDG PET-CT examination.  
Figure 13 shows transversal and coronal slice including GTV for patient 1. Changes in lung 
anatomy over time are obvious. It appears that the lung is progressively occupied by tumor tissue 
and possibly also some pleural fluid. The patient died before reaching the post-therapy session. 
 
Figure 13: CT scans of patient 1 at different time points. The left column corresponds to 
planning CT, the middle to pre-treatment, and the right to mid -treatment. The upper and lower 
images correspond to the axial and coronal plane, respectively. 
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Figure 14 shows transversal and coronal slices for patient 4. As opposed to patient 1 above, the 
lung anatomy is more stable over time. The patient lived 14 months after post-therapy 
examination. 
 
Figure 14: CT scans of patient 4 at different time points. The first column from left corresponds 
to planning CT, the second to pre-treatment, the third to mid-treatment, and the forth to post-
treatment. The upper and lower images correspond to the axial and coronal plane, respectively. 
PET images can be condensed, as explained in section 3.3, to histograms for further analysis. As 
an example, histograms of the GTV of patient 21 (Figure 15) were plotted for three sessions. By 
looking at pre-therapy histogram, we realize that SUVmax was about 21. The histogram was 
shifted towards the lower values as large parts of the tumor have values close to 2. In the 
histogram plotted for the mid-therapy, SUVmax increased to 23. The histogram has more or less the 
same shape as for pre-therapy with a slight shift towards higher values. In the histogram plotted for post-
therapy, SUVmax decreased to 14.  
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Figure 15:  GTV histograms plotted for patient 21. 
4.2. Glucose metabolism 
4.2.1. Temporal characteristics 
In this part, box plots for SUVs were generated to demonstrate the spread of the glucose uptake 
value across all available sessions for GTV and various organs such as lung, esophagus, heart, 
and bone marrow. These plots demonstrate how SUVs are distributed in each session and 
whether there are potential unusual observations in the data set.   
The Box-whisker plot (Figure 16) shows an overall distribution of SUVs in GTV for the 
available sessions across all patients. The mean value was greater than the median value, this 
expresses that data was “skewed” towards the lower SUV values. The difference between mean 
and median was quite apparent for some patients. For instance, in patient 7, we observed 
SUVmean–SUVmedian=2.7 in both sessions. The reason for such a large difference could be the 
observation of very large SUVmax for this patient; the SUV distribution for this patient is more 
skewed compared to other patients. Other notable patients with large differences in SUVmean and 
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SUVmedian were patient 21 and patient 16. Comparably, some patients (such as patient 6) have 
had more symmetrical SUV distributions. 
  
Figure 16: Box-whisker plot showing the overall distribution of SUVs in the tumor for the 
available sessions across all patients. 
The Box plot in Figure 17 shows the SUV distribution in the heart. It was evident that SUVmin 
was about 0.2 for all patients while SUVmax differed dramatically across patients (from 3.2 to 
21.5). The SUV distribution was rather narrow for most of the patients and small differences 
between mean and median of SUV implied a symmetrical distribution of glucose uptake in the 
heart. Again, SUVmean > SUVmedian showed a skewed distribution towards lower values. 
Relatively large SUVmean – SUVmedian in few patients was a result of high maximum in SUVs. 
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Figure 17:  Box-whisker plot showing the overall distribution of SUVs in heart for the available 
sessions across all patients. 
SUV distribution in esophagus is plotted against the session of a given patient’s examination in a 
Box plot (Figure 18). SUVmin was between 0.1 and 0.5 for all data. SUVmax ranged between 2 
and 7 for most patients. Patient 10 again had a very high SUVmax (over a value of 15) compared 
to other patients.   
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Figure 18: Box-whisker plot showing the overall distribution of SUVs in esophagus for the 
available sessions across all patients. 
The Box plot in Figure 19 shows the SUV distribution in the bone marrow. The difference 
between first and third quartiles (or interquartile) was relatively narrow. SUVmax – SUVmin was 
less than 7 for most patients. SUVmin was close to 0.2 for most patients. Patients 10 and 21 had a 
SUVmax that is dramatically larger than for the other patients. 
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Figure 19: Box-whisker plot showing the overall distribution of SUVs in bone marrow for the 
available sessions across all patients. 
The Box plot in Figure 20 shows the SUV distribution in the ipsilateral lung. In this plot a wide 
range of SUVmax can be seen. The interquartile was relatively small. Patient 21 (at pre-therapy 
session and post-therapy session) and patient 10 (at pre-therapy session) had the largest value 
of SUVmax, which was approximately 18. 
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Figure 20: Box-whisker plot showing the overall distribution of SUVs in ipsilateral lung for the 
available sessions across all patients. 
The Box plot in Figure 21 shows the SUV distribution in the contralateral lung. It can be 
observed that SUVmin was close to 0.1 for most patients, while SUVmax differed from patient to 
patient and across sessions. The two highest SUVmax’s of 9 and 10 belonged to patient 11 and 10 
at mid-therapy session, respectively. Patient 1 had the largest interquartile compared to other 
patients.  
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Figure 21: Box-whisker plot showing the overall distribution of SUVs in contralateral lung for 
the available sessions across all patients. 
4.2.2. Time trends 
In the following, the temporal changes observed in SUVs are presented. The following plots 
were made based on different statistical values such as SUVmean, SUVmedian and SUVmax for 
patients in various sessions. The average of the data points was also shown (as a red square) in 
the diagrams. Results were further expressed as SUVmean ±SD (Standard Deviation) for all 
patients across sessions. Mann-Whitney U-test then was used when searching for significant 
differences between these two groups in each session (Table 7). 
In Figure 22, SUVmax from patients’ GTV were plotted across sessions. A large heterogeneity in 
the changes of SUVmax for GTV was observed during radiotherapy for the patients. The SUVmax 
was 12.6±6.0 before start of radiotherapy (pre-therapy session), which slightly increased to 
13.0±6.1 at mid-therapy session. Six weeks after radiotherapy (post-therapy), SUVmax decreased 
to 9.5±4.4. Analyzing the subset of patients (n = 5), who underwent 
18
F-FDG PET-CT scan at all 
three sessions, a progressive decrease were observed: the SUVmax at pre-therapy was 13.1±7.3 
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(range: 2.9–20.9), at mid-therapy it was 12.5±7.6 (range: 2.7–22.6), and at post-therapy it was 
8.7±4.9 (range: 3.5–14.1). 
 
Figure 22: SUVmax in GTV plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients. The population-based mean is given by a red square. 
In Figure 23 the progressive decrease was also observed for SUVmean in the GTV across the 
sessions for all patients and subset of patients who underwent 
18
F-FDG PET-CT scan at all three 
sessions (n=5). 
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Figure 23: SUVmean in GTV plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients. The population-based mean is given by a red square.  
In Figure 24, SUVmax for all delineated lymph nodes were plotted across sessions. Some patients 
did not have any delineated lymph nodes while others have up to 11 lymph nodes (Table 9). A 
large heterogeneity in lymph nodes’ SUVmax was observed during the radiotherapy between 
patients. The SUVmax was 9.7±8.6 at pre-therapy, which slightly decreased to 8.8±6.9 at mid-
therapy. At post-therapy, SUVmax further decreased to 6.0±8.7. 
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Figure 24: SUVmax in lymph nodes plotted versus session (before start of RT, mid therapy and 6 
weeks after RT) for all individual patients. The population-based mean is given by a red square. 
In Figure 25, SUVmedian from patients’ lung were plotted across sessions. SUVmedian in the lung 
was 0.57±0.2 at pre-therapy session, which increased to 0.62±0.2 at mid-therapy session. 
SUVmedian further increased to 0.70±0.2 at post-therapy session. Analyzing the subset of patients 
(n = 5), who underwent 
18
F-FDG PET-CT scan at all three sessions, a similar trend were 
obtained: the SUVmax at pre-therapy was 0.53±0.2, at mid-therapy it was 0.65±0.3, and at post-
therapy it was 0.71±0.3. 
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Figure 25: SUVmedian in lung plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients. The population-based mean is given by a red square.  
Classifying the lung into ipsilateral and contralateral lung also showed a progressive increase. 
The SUVmedian for contralateral lung (Figure 26) was 0.47±0.1 at pre-therapy, 0.54±0.2 at mid-
therapy, and 0.65±0.2 at post-therapy. For ipsilateral lung (Figure 27), SUVmedian at pre-, mid-, 
and post-therapy sessions was 0.67±0.3, 0.71±0.3, and 0.74±0.3, respectively.  
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Figure 26: SUVmedian in contralateral lung plotted versus session (before start of RT, mid therapy 
and 6 weeks after RT) for all individual patients. The population-based mean is given by a red 
square. 
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Figure 27: SUVmedian in ipsilateral lung plotted versus session (before start of RT, mid therapy 
and 6 weeks after RT) for all individual patients. The population-based mean is given by a red 
square.  
In Figure 28, SUVmedian from patients’ bone marrow were plotted across sessions. SUVmedian For 
the bone marrow at pre-therapy was 1.3±0.2. This value increased to 1.5±0.4 at mid-therapy 
session. Likewise at post-therapy session, SUVmedian was 1.5±0.2. Analyzing the subset of 
patients (n = 5), who underwent 
18
F-FDG PET-CT scan at all three sessions; similar results were 
obtained. Here, SUVmedian at pre-therapy session was 1.2±0.1, at mid-therapy it was 1.4±0.2, and 
at post-therapy it was 1.4±0.2.  
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Figure 28: SUVmedian in bone marrow plotted versus session (before start of RT, mid therapy and 
6 weeks after RT) for all individual patients. The population-based mean is given by a red 
square.  
In Figure 29, SUVmedian from patients’ esophagus were plotted across sessions. SUVmedian in the 
esophagus was 1.5±0.4 at pre-therapy. This value increased to 1.8±0.4 at mid-therapy session. 
Likewise at post-therapy session, SUVmedian was 1.8±0.2. A progressive increase was observed 
by analyzing the subset of patients (n = 5) who underwent 
18
F-FDG PET-CT scan at all three 
sessions. The SUVmedian at pre-therapy session was 1.4±0.2, at mid-therapy it was 1.6±0.3, and at 
post-therapy it was 1.8±0.3. 
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Figure 29: SUVmedian in esophagus plotted versus session (before start of RT, mid therapy and 6 
weeks after RT) for all individual patients. The population-based mean is given by a red square.  
In Figure 30, SUVmedian from patients’ heart were plotted across sessions. SUVmedian for the heart 
at pre-therapy was 1.9±0.5. Likewise this value was 1.9±0.4 at mid-therapy and reached 2.0±0.5 
at post-therapy session. The same trend was observed by analyzing the subset of patients (n = 5), 
who underwent 
18
F-FDG PET-CT scan at all three sessions. SUVmedian before radiotherapy (pre-
therapy session) was 2.1±0.8, at mid-therapy it was 2.1±0.4, and at post-therapy it was 2.2±0.4. 
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Figure 30: SUVmedian in heart plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients. The population-based mean is given by a red square.  
4.2.3. FDG uptake response versus dose 
This part of the study was focused on how SUV changes with dose in the mid-therapy and the 
post-therapy sessions and whether we can identify any trends in SUVmean level with RT dose. 
SUVmean was calculated in dose bins of 0.5 Gy for all patients and the mean value of SUVmean 
from all patients that belongs to each dose bin was then calculated. Because only half of the total 
RT dose was delivered at mid-therapy, the dose ranged between 0 and 15 Gy in this session. On 
the other hand, the dose was between 0 and 30 Gy at post-therapy session. Thus, data was shown 
in terms of % of delivered dose. 100% of delivered dose corresponds to 15 Gy and 30 Gy at mid- 
and post-therapy, respectively. A linear regression model was used to investigate the correlation 
between FDG uptake and dose at mid- and post-therapy. In the following plots the slope and 
intercepts are reported as an estimate ± SE (Standard Error). We also looked for statistical 
significance, both with respect to the dose response relationship and with respect to differences 
in FDG-uptake between the two imaging sessions. 95% confidence intervals were used for 
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assessing significance. Because the GTV received quite homogeneous RT doses, SUV versus 
dose plots were shown only for the OAR’s. 
Figure 31 shows SUV in the lung across all patients against percentage delivered dose at mid-
therapy and post-therapy sessions. The straight lines represent fitted regression lines for these 
sessions. The lines have positive slopes and are almost parallel. 
At mid-therapy the median of SUVmean in the lung that received 0–5 Gy was 0.70 (range, 0.66–
0.73), 5–10 Gy was 0.74 (range, 0.70–0.77), and >10 Gy was 0.77 (range: 0.74– 1.00). At post-
therapy session, the median of SUVmean in the lung that received 0–10 Gy was 0.79 (range, 0.71–
0.86), 10–20 Gy was 0.87 (0.83–0.90), and >20 Gy was 0.87 (range, 0.82–1.02). Using linear 
regression the slope at mid-therapy and post-therapy was 0.0046±0.0005 and 0.0051±0.0005, 
with a 95% CIs [0.0037, 0.0056] and [0.0042, 0.0061], respectively. The intercept at mid-therapy 
and post-therapy was 0.67±0.01 and 0.77±0.01, with a 95% CIs [0.66, 0.69] and [0.75, 0.78], 
respectively. 
 
Figure 31: SUV in the lung versus percentage delivered dose at mid-therapy and post-therapy. 
The solid lines correspond to a linear regression.  
The lung FDG uptake dose response curves corresponding mid-therapy and post-therapy from 
individual patients were generated; various slopes and their standard error were used to build up 
sensitivity plot across all available sessions (Figure 32). It can be observed that except for patient 
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3 (at mid-therapy) and for patient 21 (at mid- and post-therapy) relationship between FDG 
uptake and dose was positive. At mid-therapy, 17 patients with positive slopes had a mean of 
slopes range of 0.0018 to 0.0118. At post-therapy, 6 patients with positive slopes had a mean of 
slopes range of 0.0005 to 0.0146. Looking for patients with data in the mid-therapy and post-
therapy, we found out that in all patients except patient 9, sensitivity was higher in post-therapy 
compare to mid-therapy. 
 
Figure 32: Lung sensitivity plotted for the available sessions across all patients. 
The following organs along with their statistical properties of FDG response, SUV values for 
different dose intervals were reported in Table 3 at the end of this chapter. 
Figure 33 shows SUV in the bone marrow across all patients against percentage delivered dose at 
mid-therapy and post-therapy sessions. The straight lines represent fitted regression lines for 
these sessions. The lines have negative slopes. Using linear regression the slope at mid-therapy 
and post-therapy was –0.004±0.001 and –0.001±0.001, with a 95% CIs [–0.006, –0.003] and [–
0.004, 0.001], respectively. The intercept at mid-therapy and post-therapy was 1.66±0.01 and 
1.48±0.02, with a 95% CIs [1.63, 1.69] and [1.44, 1.52], respectively. 
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Figure 33: SUV in the bone marrow versus percentage delivered dose at mid-therapy and post-
therapy. The solid lines correspond to a linear regression.  
Figure 34 shows SUV in the esophagus across all patients against percentage delivered dose at 
mid-therapy and post-therapy sessions. The straight lines represent fitted regression lines for 
both sessions. The lines have positive slopes and are almost parallel. Using linear regression the 
slope at mid-therapy and post-therapy was 0.020±0.002 and 0.019±0.004, with a 95% CIs 
[0.016, 0.023] and [0.011, 0.026], respectively. The intercept at mid-therapy and post-therapy 
was 1.45±0.31 and 1.59±0.07, with a 95% CIs [1.39, 1.52] and [1.44, 1.73], respectively. 
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Figure 34: SUV in the esophagus versus percentage delivered dose at mid-therapy and post-
therapy. The solid lines correspond to a linear regression.  
Figure 35 shows SUV in the heart across all patients against percentage delivered dose at mid-
therapy and post-therapy sessions. The straight lines represent fitted regression lines for both 
sessions. The line that belongs to mid-therapy has a positive slope while the line that belongs to 
post-therapy has a negative slope. Using linear regression the slope at mid-therapy and post-
therapy was 0.008±0.001 and –0.004±0.002, with a 95% CIs [0.005, 0.011] and [–0.008, 0.000], 
respectively. The intercept at mid-therapy and post-therapy was 1.97±0.02 and 1.99±0.04, with a 
95% CIs [1.93, 2.02] and [1.91, 2.07], respectively. 
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Figure 35: SUV in the heart versus percentage delivered dose at mid-therapy and post-therapy. 
The solid lines correspond to a linear regression.  
4.3. Influence of Tarceva on glucose metabolism 
4.3.1. Time trends 
In total 13 patients received Tarceva, of which only 3 patients underwent all examinations. Eight 
patients were examined in the pre-therapy, 10 in the mid-therapy, and 5 in the post-therapy. In 
order to compare Tarceva receiving group of patients with the non-Tarceva receiving group, we 
calculated normalized SUV (NSUV) to measure the activity of GTV and OAR’s and to improve 
the reproducibility of this measure. NSUV (for GTV) was derived from the following equation 
for individual patients: 
)(
)(
max
max
therapypreSUV
therapymidSUV
NSUV


  
For other organs SUVmedian was used instead of SUVmax. Mann-Whitney U-test was used when 
searching for significant differences between these two groups in each session (Table 8). 
Figure 36 shows SUVmax in GTV plotted versus sessions and for patient separated into Tarceva 
and non-Tarceva receiving groups. For patients treated with both RT and Tarceva the SUVmax in 
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the tumor was 11.0±6.8 (range: 2.9–21.6) before start of radiotherapy (pre-therapy). This value 
increased to 12.5±5.8 (range: 2.7–22.6) at mid-therapy session. At post-therapy session, SUVmax 
decreased to 10.0±4.3 (range: 3.5–14.0). Analyzing the subset of patients (n = 3), who underwent 
18
F-FDG PET-CT scan in all three sessions, similar results were obtained: the SUVmax at pre-
therapy was 10.7±9.1 (range: 2.9-20.8), at mid-therapy it was 11.9±10.0 (range: 2.7–22.6), and at 
post-therapy it was 8.8±5.2 (range: 3.5–14.1). Furthermore, a progressive decrease as followed 
was seen for patients enrolled for RT arm alone: the SUVmax was 15.4±4.0 (range: 9.7–21.1) at 
pre-therapy, which decreased to 13.6±6.7 (range: 2.1–23.1) at mid-therapy. This value further 
decreased to 8.4±6.2 (range: 4.0–12.8) at post-therapy session. 
 
Figure 36: SUVmax in GTV plotted versus sessions (before start of RT, mid therapy, and 6 weeks 
after RT) for all individual patients separated into Tarceva receiving and non-Tarceva receiving 
groups. The population-based mean is given by a red square. 
Figure 37 shows SUVmean in GTV plotted versus sessions and for patient separated into Tarceva 
and non-Tarceva receiving groups. For patients treated with both RT and Tarceva the SUVmean in 
the tumor was 3.9±2.1 at pre-therapy, 3.8±1.2 at mid-therapy, and 3.0±0.8 at post-therapy. 
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Analyzing the subset of patients (n = 3), who underwent 
18
F-FDG PET-CT scan in all three 
sessions, the SUVmedian at pre-therapy was 3.6±1.5, at mid-therapy it was 3.6±1.7, and at post-
therapy it was 2.8±0.2. For patients treated with radiotherapy alone,  SUVmean was 5.0±1.2 at pre-
therapy, 4.0±1.7 at mid-therapy, and 2.4±0.6 at post-therapy session. 
 
Figure 37: SUVmean in GTV plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients separated into Tarceva receiving and non-Tarceva receiving 
groups. The population-based mean is given by a red square. 
Figure 38 shows SUVmedian in lung plotted versus sessions and for patients separated into 
Tarceva and non-Tarceva receiving groups. For patients treated with both RT and Tarceva, 
 SUVmedian in the lung was 0.5±0.2 at pre-therapy, 0.6±0.3 at mid-therapy, and 0.8±0.2 at post-
therapy session. Analyzing the subset of patients (n = 3), who underwent 
18
F-FDG PET-CT scan 
in all three sessions, the SUVmedian at pre-therapy was 0.6±0.2, at mid-therapy it was 0.8±0.3, and 
at post-therapy it was 0.9±0.2. For patients treated with radiotherapy alone, SUVmedian was 
0.6±0.3 at pre-therapy, 0.6±0.2 at mid-therapy, and 0.5±0.2 at post-therapy session. 
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Figure 38: SUVmedian in lung plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients separated into Tarceva receiving and non-Tarceva receiving 
groups. The population-based mean is given by a red square. 
Figure 39 shows SUVmedian in ipsilateral lung GTV plotted versus sessions and for patient 
separated into Tarceva and non-Tarceva receiving groups. For patients treated with both RT and 
Tarceva, SUVmedian in the ipsilateral lung was 0.6±0.2 at pre-therapy, 0.7±0.4 at mid-therapy, and 
0.8±0.3 at post-therapy session. Analyzing the subset of patients (n = 3), who underwent 
18
F-
FDG PET-CT scan in all three sessions, the SUVmedian was 0.7±0.2 at pre-therapy session, 
0.8±0.3 at mid-therapy session, and 0.9±0.3 at post-therapy session. For patients treated with 
radiotherapy alone, SUVmedian was 0.8±0.5 at pre-therapy, 0.7±0.3 at mid-therapy, and 0.5±0.2 at 
post-therapy session. 
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Figure 39: SUVmedian in ipsilateral lung plotted versus session (before start of RT, mid therapy 
and 6 weeks after RT) for all individual patients separated into Tarceva receiving and non-
Tarceva receiving groups. The population-based mean is given by a red square. 
Figure 40 shows SUVmedian in contralateral lung plotted versus sessions and for patient separated 
into Tarceva and non-Tarceva receiving groups. For patients treated with both RT and Tarceva, 
 SUVmedian in the contralateral lung was 0.5±0.2 at pre-therapy, 0.6±0.2 at mid-therapy, and 
0.7±0.2 at post-therapy. Analyzing the subset of patients (n = 3), who underwent 
18
F-FDG PET-
CT scan in all three sessions, the SUVmedian was 0.6±0.1 at pre-therapy, 0.7±0.2 at mid-therapy, 
and 0.8±0.2 at post-therapy session. For patients treated with radiotherapy alone, SUVmedian was 
0.5±0.1 at pre-therapy, 0.5±0.1 at mid-therapy, and 0.3 at post-therapy session. 
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Figure 40: SUVmedian in contralateral lung plotted versus session (before start of RT, mid therapy 
and 6 weeks after RT) for all individual patients separated into Tarceva receiving and non-
Tarceva receiving groups. The population-based mean is given by a red square. 
Figure 41 shows SUVmedian in bone marrow plotted versus sessions and for patient separated into 
Tarceva and non-Tarceva receiving groups. For patients treated with both RT and Tarceva, 
the SUVmedian in the bone marrow was 1.3±0.3 at pre-therapy, 1.6±0.2 at mid-therapy, and 
1.6±0.1 at post-therapy session. Analyzing the subset of patients (n = 3), who underwent 
18
F-
FDG PET-CT scan in all three sessions, the SUVmedian at pre-therapy was 1.2±0.2, at mid-therapy 
and post-therapy it was 1.5±0.1. For patients treated with radiotherapy alone, SUVmedian was 
1.3±0.2 at pre-therapy, 1.4±0.5 at mid-therapy, and 1.2±0.1 at post-therapy session.   
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Figure 41: SUVmedian in bone marrow plotted versus session (before start of RT, mid therapy and 
6 weeks after RT) for all individual patients separated into Tarceva receiving and non-Tarceva 
receiving groups. The population-based mean is given by a red square. 
Figure 42 shows SUVmedian in esophagus plotted versus sessions and for patient separated into 
Tarceva and non-Tarceva receiving groups. For patients treated with both RT and Tarceva, 
the SUVmedian in the esophagus was 1.4±0.3 at pre-therapy, 1.7±0.2 at mid-therapy, and 1.8±0.2 
at post-therapy session. Analyzing the subset of patients (n = 3), who underwent 
18
F-FDG PET-
CT scan in all three sessions, the SUVmedian at pre-therapy was 1.4±0.1, at mid-therapy it was 
1.6±0.1, and at post-therapy it was 1.7±0.2. In patients treated with radiotherapy alone, SUVmedian 
was 1.7±0.4 at pre-therapy, 1.9±0.5 at mid-therapy, and 1.9±0.4 at post-therapy session.   
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Figure 42: SUVmedian in esophagus plotted versus session (before start of RT, mid therapy and 6 
weeks after RT) for all individual patients separated into Tarceva receiving and non-Tarceva 
receiving groups. The population-based mean is given by a red square. 
Figure 43 shows SUVmedian in heart plotted versus sessions and for patient separated into Tarceva 
and non-Tarceva receiving groups. For patients treated with both RT and Tarceva, the SUVmedian 
in the heart was 1.9 ± 0.4 at pre-therapy, 2.0±0.3 at mid-therapy, and 2.0±0.5 at post-therapy 
session. Analyzing the subset of patients (n = 3), who underwent 
18
F-FDG PET-CT scan in all 
three sessions, the SUVmedian before radiotherapy (pre-therapy) was 1.9±0.5, at mid-therapy it 
was 2.1±0.5, and in post-therapy it was 2.3±0.4. For patients treated with radiotherapy alone, 
SUVmedian was 2.0±0.7 at pre-therapy, 1.8±0.4 at mid-therapy, and 2.0±0.4 at post-therapy 
session.   
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Figure 43: SUVmedian in heart plotted versus session (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients separated into Tarceva receiving and non-Tarceva receiving 
groups. The population-based mean is given by a red square. 
4.3.2. FDG uptake response versus dose 
This part of the study was focused on how SUV changes with dose at mid-therapy or at post-
therapy sessions when Tarceva receiving patients and non-Tarceva receiving patients were 
separated. SUVmean was calculated in each dose bin of 0.5 Gy for all patients and the mean value 
of SUVmean that belongs to each dose bin was then calculated. A linear regression model was 
used to investigate the correlation between FDG uptake and dose. In the following plots the slope 
and intercepts are reported as an estimate ± SE (Standard Error). We also looked for statistical 
significance, both with respect to the dose response relationship and with respect to differences 
in FDG-uptake between the two groups of patients (Tarceva receiving and non-Tarceva 
receiving) in each session (mid-therapy and post-therapy). 95% confidence intervals were used 
for assessing significance. The following organs along with their statistical properties of FDG 
response were reported in Table 4 at the end of this chapter. 
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Figure 44 shows SUV in the lung across all patients against delivered dose at mid-therapy 
session. These plotted data are separated into two groups, Tarceva receiving patients and non-
Tarceva receiving patients. The straight lines represent fitted regression lines for these groups. 
The lines have positive slopes and are almost parallel. 
At mid-therapy, the SUV in the lung that received 0-15 Gy was ranging between 0.59 and 0.83 
for patients who were treated with radiotherapy alone. This value was between 0.69 and 0.87 for 
patients who were treated with both Tarceva and radiotherapy. Using linear regression the slope 
for non-Tarceva patients and Tarceva patients was 0.005±0.001 and 0.004±0.000, with a 95% 
CIs [0.003, 0.006] and [0.003, 0.005], respectively. The intercept for non-Tarceva patients and 
Tarceva patients was 0.622±0.010 and 0.722±0.001, with a 95% CIs [0.599, 0.646] and [0.708, 
0.736], respectively. 
 
Figure 44: SUV in the lung versus delivered dose at mid-therapy across patients separated into 
Tarceva receiving and non-Tarceva receiving groups. The solid lines correspond to a linear 
regression. 
Figure 45 shows SUV in the lung across all patients against delivered dose at post-therapy 
session. The plotted data are separated into two groups, Tarceva receiving patients and non-
Tarceva receiving patients. The straight lines represent fitted regression lines for these groups. 
The lines have positive slopes but the line fitted on non-Tarceva group is much steeper. 
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 At post-therapy, the SUV in the lung that received 0-30 Gy was ranging between 0.37 and 0.88 
for patients who were treated with radiotherapy alone. This value was between 0.79 and 1.05 for 
patients who were treated with both Tarceva and radiotherapy. Using linear regression the slope 
for non-Tarceva patients and Tarceva patients was 0.010±0.001 and 0.003±0.001, with a 95% 
CIs [0.009, 0.011] and [0.002, 0.004], respectively. The intercept for non-Tarceva patients and 
Tarceva patients was 0.40±0.01 and 0.88±0.01, with a 95% CIs [0.38, 0.42] and [0.86, 0.90], 
respectively. 
 
Figure 45: SUV in the lung versus percentage dose at post-therapy across patients separated 
into Tarceva receiving and non-Tarceva receiving groups. The solid lines correspond to a linear 
regression.  
Figure 46 shows SUV of the bone marrow across all patients against delivered dose at mid-
therapy session. These plotted data separated into two groups, Tarceva receiving patients and 
non-Tarceva receiving patients. The straight lines represent fitted regression lines for these 
groups. The lines have negative slopes. The line fitted on non-Tarceva group is much steeper 
than for Tarceva group. 
At mid-therapy session, the SUV in the bone marrow that received 0-15 Gy was ranging between 
1.30 and 1.92 for patients who were treated with radiotherapy alone. This value was between 
1.40 and 1.82 for patients who were treated with both Tarceva and radiotherapy. Using linear 
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regression the slope for non-Tarceva patients and Tarceva patients was –0.006±0.001 and –
0.003± 0.001, with a 95% CIs [–0.009, –0.003] and [–0.005, –0.001], respectively. The intercept 
for non-Tarceva patients and Tarceva patients was 1.66±0.03 and 1.66±0.02, with a 95% CIs 
[1.60, 1.73] and [1.62, 1.70], respectively. 
 
Figure 46: SUV in the bone marrow versus delivered dose at mid-therapy across patients 
separated into Tarceva receiving and non-Tarceva receiving groups. The solid lines correspond 
to a linear regression.  
Figure 47 shows SUV in the bone marrow across all patients against delivered dose at post-
therapy session. These plotted data separated into two groups, Tarceva receiving patients and 
non-Tarceva receiving patients. The straight lines represent fitted regression lines for these 
groups. These lines have negative slopes. 
At post-therapy, the SUV in the bone marrow that received 0-30 Gy was ranging between 1.09 
and 1.69 for patients who were treated with radiotherapy alone. This value was between 1.19 and 
1.82 for patients who were treated with both Tarceva and radiotherapy. Using linear regression 
the slope for non-Tarceva patients and Tarceva patients was –0.003±0.001 and –0.001±0.001, 
with a 95% CIs [–0.006, 0.000] and [–0.004, 0.002], respectively. The intercept for non-Tarceva 
patients and Tarceva patients was 1.37±0.03 and 1.53±0.03, with a 95% CIs [1.30, 1.43] and 
[1.47, 1.59], respectively. 
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Figure 47: SUV in the bone marrow versus delivered dose at post-therapy across patients 
separated into Tarceva receiving and non-Tarceva receiving groups. The solid lines correspond 
to a linear regression.  
4.4. Tissue density 
4.4.1. Temporal characteristics 
Box plot of HUs were generated to demonstrate the density distribution across three sessions for 
GTV and lung. These plots display data broken down into three quartiles, which was described 
in section 3.4.  
The Box-whisker plot (Figure 48) showed an overall distribution of tumor density for the 
available sessions across all patients. The median value was greater than the mean value and 
express that data is “skewed” toward the higher density. Heterogeneity of the tumor was varied 
from patient to patient. 
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Figure 48: Box-whisker plot showing the overall distribution of density in GTV for the available 
sessions across all patients
15
. 
The Box-whisker plot (Figure 49) showed an overall distribution of lung density for the available 
sessions across all patients. In this plot we observed that the lung heterogeneity varied from 
patient to patient. All patients had the same CT Numbermin and    Numbermax (100 and 800 
respectively) because, as mentioned in section 3.2.3, we limited the CT number to these 
numbers. 
 
                                                 
15
  CT Numbers here are equal to the CT numbers which were extracted from the codes and were not converted to 
HU. For conversion formula in section 3.2.2 is used. 
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Figure 49: box-whisker plot showing the overall distribution of density in lung for the available 
sessions across all patients (*the legend is the same as for Figure 48). 
4.4.2. Time trend 
 
In Figure 50 HUmedian in the lung for all patients were plotted across sessions. HUmedian in the 
lung was –774.1 (range, –869.6 to –468.2) at pre-therapy, which increased to –763.4 (range, –
865.7 to –471.2) at mid-therapy. This value further increased to –753.6 (range, –864.8 to –642.7) 
at post-therapy session. 
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Figure 50: HUmedian in the lung plotted versus time (before start of RT, mid therapy and 6 weeks 
after RT) for all individual patients with a CT-PET scans. 
4.4.3. HU response versus dose 
To determine the changes in lung density as a function of dose in the mid-therapy and in the 
post-therapy session HUmean was calculated in each dose bin of 0.5 Gy for all patients and the 
mean value of HUmean that belongs to each dose bin was then calculated. 100% delivered dose 
corresponds to 15 Gy for mid-therapy session and 30 Gy for post-therapy session. A linear 
regression model was used to investigate the correlation between HU and dose at mid- and post-
therapy. In the following plots the slope and intercepts are reported as an estimate ± SE 
(Standard Error). 95% confidence interval statistical test was then used for validation of the 
significant differences between the two sessions. 
Figure 51 shows HU in the lung across all patients against percentage delivered dose at mid-
therapy and post-therapy sessions. The straight lines represent fitted regression lines for these 
sessions. The lines have positive slopes. The line that belongs to post-therapy has a steeper slope. 
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 At mid-therapy, the median of HUmean in the lung that received 0–5 Gy was –722.1, 5–10 Gy 
was –714.9, and >10 Gy was –711.6. At post-therapy session, the median of HUmean in the lung 
that received 0–10 Gy was –710.1, 10–20 Gy was –701.1, and >20 Gy was –691.9.  
Using linear regression the slope at mid-therapy and post-therapy was 0.66±0.10 and 1.55±0.2, 
with a 95% CIs [0.34, 0.98] and [1.11, 1.99], respectively. The intercept at mid-therapy and post-
therapy was –725.2±2.9 and –718.6±3.9, with a 95% CIs [–731.0, –719.4] and [–726.6, –710.7], 
respectively. 
 
Figure 51: HU in the lung versus percentage delivered dose at mid-therapy and post-therapy. 
The solid lines correspond to a linear regression.  
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5. Discussion 
5.1. Critical appraisal 
In this study, twenty two patients with NSCLC, 6 women and 16 men at the average age of 70 
years (range: 60–81), were included. Post 18F-FDG PET-CT examination couldn’t be performed 
on 15 patients due to rapid progression of disease, death, or that patients did not show up at the 
imaging session.  Three patients were not examined at mid-therapy. Furthermore, eight patients 
missed their first 
18
F-FDG PET-CT examination. The limited number of patients in this project 
and the missing data for sessions, especially for session three, introduces difficulties in drawing 
solid conclusions. Other issues to consider include: 1) the fact that blood sugar for patient 1 was 
higher than a normal range (above 8 mMol/L), 2) the time interval between pre-therapy and mid-
therapy was too long for two patients (65 and 34 days for patient 6 and 8, respectively), 3) the 
incubation time was more than the normal range (60–80 min) for patient 3 and 19 at pre-therapy 
session and for patient 1 at mid-therapy. 
Lung cancer patients may have other lung diseases such as Chronic Obstructive Pulmonary 
Disease (COPD). The involvement of inﬂammatory cells in the pathogenesis of COPD is well 
established and FDG uptake is greater in COPD than in normal subjects (22). SUV level from 
patients with COPD could be higher and this could be a source of error. COPD status was not 
recorded in the current investigation. 
Another issue that should be taken into account is that, for some patients (Figure 13), a fluid 
accumulation in the lung (called pleural effusion) caused by the cancer was observable. The 
pleural fluid causes difficulties in scoring one-to-one voxel associations in the HU analysis of the 
lung. 
Having only one set of delineations on planning CT may be problematic especially for patients 
with rapid disease progression. In other words, tumor volume changes from planning CT to the 
last 
18
F-FDG PET-CT examination may occur, but only data from within the early tumor volume 
is scored. This also affects the lung volume, especially in ipsilateral lung. Still, error in lung data 
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is minimized by introducing the CT window for lung tissue at all sessions. Some patients may 
have tumor masses in both lungs, and spread of the cancer cells during the treatment. This can 
affect the data of ipsilateral and contralateral lungs, since the lung with the largest tumor volume 
is used as ipsilateral lung. 
Originally, there were two Tarceva arms (+ one RT arm) in the clinical study. In one arm, 
patients were given Tarceva from the first to the last day of radiotherapy. In the second arm, 
patients kept receiving Tarceva after the end of the radiotherapy. In the analysis, these two trial 
arms are mixed together, which could give rise to uncertainties with respect to assessing the 
effects of Tarceva. 
Correction for blood glucose level in individual patients is not performed in the estimated SUVs. 
However, the strong correlation between SUV and blood glucose concentration suggests that for 
non-diabetic fasted patients, lung tumor SUVs should not be adjusted for blood glucose level 
(23).  
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5.2. Gross Tumor Volume 
5.2.1. Time trend in SUV 
Hebert et al. (24) showed that in terms of  measuring the response to radiotherapy, metabolic 
changes are more sensitive than morphological (structural) changes. This study focused on the 
effect of radiotherapy on FDG uptake from PET imaging of 20 patients who were examined 
before and after radiotherapy. It was one of the first studies to incorporate a larger sample of 
patients. This study has been followed up by several articles reporting that 
18
F-FDG PET-CT 
detects metabolic alterations before morphologic ones (25) (26). 
In 2007 two groups published results from repeated 
18
F-FDG PET-CT before, during, and after 
radiotherapy. Baardwijk et al. (26) performed 
18
F-FDG PET-CT scans on 23 patients with 
medically inoperable or advanced NSCLC, before start of radiotherapy, on day 7 and 14 during 
radiotherapy, and 70 days after radiotherapy. Radiotherapy was delivered twice a day with a 
fraction size of 1.8 Gy. Investigating the time trends, they observed an increase in SUVmax during 
the first week of RT, followed by a decrease in the second week and 70 days after treatment. A 
large heterogeneity in the SUVmax in repeated PET scans was also observed between the 
individual patients. Furthermore, Kong et al. (25) investigated changes in SUV in 15 patients 
with NSCLC (stages I to III) with 
18
F-FDG PET-CT performed two weeks before RT, during RT 
(after delivery of 45 Gy), and 3 to 4 months after RT. Radiotherapy was delivered with 30 daily 
fractions with a fraction size ranging from 2.2 to 3.4 Gy. The authors observed a significant 
reduction in SUVpeak mid-therapy, with a further reduction in this value post-therapy.  
Giovacchini et al. (27) performed four repeated 
18
F-FDG PET-CT scans in 6 patients with 
NSCLC who were not amendable to surgical treatment. The scans were taken before RT, during 
radiotherapy (at the median of 14 days before the end of radiotherapy), and at two instances after 
radiotherapy (at a median of 28 and 93 days respectively). Radiotherapy was delivered with a 
total dose between 60-70.2 Gy with a fraction size ranging from 1.8 to 2.0 Gy. Radiotherapy 
induced a progressive decrease in SUVmax. The decrease was more evident three months after 
radiotherapy but could also be detected during the treatment. No significant differences in 
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SUVmax were found between the last two sessions. More recently, Massaccesi et al. (28) 
performed three series of 
18
F-FDG PET-CT in 25 patients with NSCLC: before treatment, during 
the third week of concurrent chemo-radiotherapy, and four weeks after the end of treatment. A 
total dose of 50.4 Gy was delivered with a fractionation of 1.8 Gy per day. The authors observed 
that the tumor metabolic activity (SUVmax) significantly decreased during chemo-radiotherapy, 
and decreased even more at the post therapy session. 
The aim of this part of the current study was to evaluate changes in the uptake of FDG on PET 
scans performed before, during, and after radiotherapy in patients with NSCLC. A large 
heterogeneity in tumor metabolic activity (SUVmax and SUVmean) among the individual patients 
before treatment may suggest a large cellular heterogeneity between tumors. In our observation 
the average of SUVmax pre-therapy is much higher than that reported by Baardwijk (26), but 
more similar to those reported by Giovacchini (27) and Massaccesi (28). There are various 
mechanisms that could potentially affect the level of FDG uptake. Mechanisms such as the up-
regulation of glucose transporters and hexokinase enzymes (29), hypoxia (30), and tumor 
aggressiveness and proliferation (31) (32) could enhance trapping of FDG in the tumor cells. We 
observed a significant (      ) reduction in SUVmax from the pre-therapy to the post-therapy 
session, in line with the studies previously mentioned. The insignificant decrease in maximal 
tumor metabolic activity from the pre-therapy session to the mid-therapy session may imply that 
the time window of 5 days is not appropriate (too small) to see changes in FDG uptake in the 
course of radiotherapy. However, the optimal time to perform 
18
F-FDG PET-CT examination 
during the treatment is remained unclear.  Massaccesi et al. (28) reported a significant decrease 
in the tumor metabolic activity after an RT dose of 23.4 Gy (total dose of 50.4 Gy, fractionation 
of 1.8 Gy/day). In contrast, Baardwijk et al. (26) did not observe any significant decrease in 
tumor metabolic activity after 14 days (1.8 Gy twice a day). Differences in the radiotherapy 
fractionation schedule, treatment time, concurrent chemotherapy administration, tumor biology, 
and pre-treatment SUVmax values might also have an impact on tumor FDG uptake during 
radiotherapy. Small sample size considerably limited the statistical inference to detect significant 
changes in glucose metabolism over time.  
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According to the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 
guidelines, a 30% reduction in tumor FDG uptake is defined as metabolic response (33). In 
addition, an absolute reduction of at least 0.8 SUV is also required. By calculating changes in 
tumor SUVmax between all available sessions for individual patients and using PERCIST criteria, 
tumor metabolic response was found in a few of patients (Table 5). On the other hand, no 
significant decrease was found in SUVmean. This may imply that SUVmax was the more sensitive 
parameter to show metabolic modification induced by the treatment. 
Table 5: Percentage change in tumor SUVmax between all available sessions for individual 
patients. Negative values represent a reduction in SUVmax while positive values represent an 
increase in SUVmax.  
Patient’s ID 
% change, pre- to mid-
therapy 
% change, mid- to post-
therapy 
% change, pre- to post-
therapy 
1 9.9 
  
2 -9.9 
  
3 
 
-8.5 
 
4 -44.7 -58.7 -77.1 
6 -4.7 28.0 21.9 
7 9.5 
  
8 -22.9 
  
9 22.1 -12.4 6.9 
10 -82.4 
  
12 7.7 -25.0 -19.2 
16 28.2 
  
20 
 
-40.3 
 
21 8.6 -37.7 -32.3 
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5.2.2. Influence of Tarceva 
Over the last decade, several molecular targeted agents, such as Tarceva or gefitinib
16
 have 
emerged for treatment of NSCLC. Tarceva is one of the most widely studied targeted agents, and 
have been used in clinical trials for patients with NSCLC. However, research concerning 
response monitoring with 
18
F-FDG PET-CT for targeted therapies is scare. The first report on the 
value of PET in evaluation of early response to targeted therapies emerged in 2003. Here, 
Stroobants et al. (34) reported that a PET response was observed in 13 out of 21 patients with 
gastrointestinal stromal tumors (GISTs) after 8 days of treatment with Imatinib. 
Two groups has reported that 
18
F-FDG PET-CT may detect tumor changes occurring as early as 
2 days after start of Tarceva treatment, which can predict early response in NSCLC patients (35) 
(36). In contrast, Ullrich and colleagues (37) reported that 
18
F-FDG PET-CT failed to robustly 
identify the responding tumors after two days of treatment (using PC9 and the HCC827 
xenografts in nude mice). They suggest that glucose metabolism rather indirectly reflects tumor 
cell proliferation and therefore is not a suitable marker for Tarceva at early stage of treatment. 
Aukema et al. (38) studied whether 
18
F-FDG PET-CT could predict response to Tarceva for 
patients with NSCLC. In that study, 23 patients with non-small cell lung cancer who were 
eligible for surgical resection were evaluated. All patients received neoadjuvant Tarceva once 
daily for 3 weeks and two series of 
18
F-FDG PET-CT were performed before and one week after 
the administration of Tarceva. 6 of 23 patients (26%) showed metabolic response
17
 within one 
week of treatment, 16 patients (70%) showed stable disease and 1 patient (4%) showed 
progressive disease. This study suggested that during the early course of Tarceva therapy for 
NSCLC, 
18
F-FDG PET-CT can identify response in most patients. In contrast, Hachemi et al. 
(39) performed three series of 
18
F-FDG PET-CT on 12 patients with stage IIIA to IV NSCLC. 
Scans acquired before (5±4 days) and after (9±3 days and 60±6 days) Tarceva therapy, with a 
                                                 
16
 Another EGF Receptor blocker 
17
  Metabolic response was defined as a decrease of at least 25% in SUVmax using European Organization or Re-
search and Treatment of Cancer (EORTC). 
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median duration of 75 days. It was found that the tumor SUVmax did not vary significantly over 
time. 
Based on our results, no significant changes were found in the tumors’ SUVmax for patients 
receiving Tarceva during the imaging sessions. This could suggest that 
18
F-FDG PET-CT is not a 
suitable biomarker to monitor Tarceva treatment. The other possibility might be that Tarceva did 
not significantly affect the tumor during mid- or post-therapy sessions. Furthermore, no 
significant differences were found in the tumor SUVmax between patients receiving and not 
receiving Tarceva in each imaging session. It could be that the patients included in the current 
study had such an aggressive disease that the tumors did respond to neither radiotherapy nor 
Tarceva therapy. 
5.3. Lymph nodes 
5.3.1. Time trend in SUV 
Kong et al. (25) and Massaccesi et al. (28) also investigated the effect of radiotherapy on lymph 
nodes’ metabolic activity before, during, and after treatment. Kong et al. (25) reported that FDG 
activity of metastatic lymph nodes decreased during radiotherapy, without any significant 
differences between mid-therapy and post-therapy. On the other hand, Massaccesi et al. (28) 
reported that lymph nodes’ metabolic activity decreased at the end of treatment. Based on our 
results, no significant changes in SUVmax were observed between sessions. This could imply that 
lymph nodes are more resistant to treatment than tumors. It has been reported that neoplastic 
lymph nodes are a negative prognostic factor in patients with NSCLC (40). 
5.4. Lung 
Lung is one of the most relevant organs at risk in the treatment of thoracic cancer. The lung is a 
complex organ consisting of over 40 types of cells [reported by Sorokin et al. cited in (13)], and 
the mechanisms leading to radiation induced lung injury is not completely understood. A number 
of studies has attempted to determine the mechanisms leading to radiation induced lung injury. It 
has been reported that the early clinical phase of radiation effects in the lung becomes apparent at 
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about 1–3 months after radiotherapy, with congestion, cough, dyspnea, fever, and chest pain 
caused by inflammation (41). 
5.4.1. Time trend in SUV 
Hicks et al. (42) performed a qualitative evaluation of metabolic changes within the irradiated 
lung volume which was beyond the regions of tumor. 
18
F-FDG PET-CT scans before treatment 
and post treatment were performed on 73 patients with NSCLC treated with radical RT or chemo 
irradiation. The authors found a positive correlation between the degree of radiation-induced 
change in irradiated normal tissues (lung and pleura), and the degree of both metabolic and CT 
response. These post treatment changes were most likely due to radiation pneumonitis (RP) and 
pleuritis
18
. Furthermore, a metabolic response in the normal lung and RP seemed to be associated 
with a higher probability of tumor response. 
Kong et al. (25) performed a pilot study and investigated changes in SUV in 15 patients with 
NSCLC (stages I to III). 
18
F-FDG PET-CT scans were performed two weeks before RT, during 
RT (after delivery of 45 Gy), and 3 to 4 months after RT. Radiotherapy was delivered with 30 
daily fractions with a fraction size ranging from 2.2 to 3.4 Gy. The authors found that there was 
no significant increase in SUVpeak activity within irradiated lung between pre-RT and mid-RT, 
while the FDG uptake within irradiated lung was significantly higher on the post-RT scans.   
Ruysscher et al. (43) performed three series of 
18
F-FDG PET-CT scans, one before RT (on day 
0) and two during RT (on days 7 and 14), on 18 patients with stage III non-small cell lung 
cancer. Radiotherapy (with a total dose range of 54.0 to 79.2 Gy) was delivered twice daily with 
a fraction size of 1.8 Gy. The authors observed that patients without RILT (Radiation Induced 
Lung Toxicity) had a stable SUVmax in the lungs between days 7 and 14; while patients with 
RILT had an increased SUVmax in the lungs during RT. 
Based on our results there were no significant differences in SUVmedian (Figure 25) and SUVmax 
(data not shown) in lung among different imaging sessions. We speculate that this could 
                                                 
18
  an inflammation of the pleura 
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probably be the result of using SUV data from the entire lung. For example the SUV level in 
Kong et al. (25) study came from the irradiated lung and not the whole lung. Since a palliative 
regime was used for treating patients, all parts of the lung have received a dose in the current 
study. Thus, we decided to exclude parts of the lung that received relatively small amounts of 
radiation. First we extracted the part of the lungs that received 10 Gy or more (V10), and 
calculated the 90
th
 percentile of the resulting SUV distribution (SUV90). Then the lung volume 
receiving 20 Gy or more was extracted, and SUV90 was calculated. The data are shown in Figure 
52 and Figure 53, using V10 and V20, respectively. Even with this refinement, no significant 
differences were found in lung SUV90 using Mann-Whitney U-test on the modified data. 
 
Figure 52: SUV90 in lung plotted versus imaging session (before start of RT, mid therapy and 6 
weeks after RT) for all individual patients, using SUV data from voxels which received 10 Gy or 
higher. 
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Figure 53: SUV90 in lung plotted versus time imaging session (before start of RT, mid therapy 
and 6 weeks after RT) for all individual patients with a 
18
F-FDG PET-CT scans, using SUV data 
from voxels which received 20 Gy or higher . 
Another possibility for the lack of response in the normal lung could be that the duration of six 
weeks after RT is not long enough to see significant changes in the lung metabolism. In other 
words, more time may be needed to observe radiation induced metabolic changes with PET in 
lung, as was indicated by Kong and colleagues (25) three to four months after RT. Moreover, 
based on the study by Ruysscher and colleagues (43), we can speculate that most of the patients 
did not develop RILT after completion of treatment. However, patients in this study were not 
evaluated for RILT, and this conclusion thus remains untestable. 
5.4.2.  FDG uptake response versus dose 
In order to have a better understanding of any RT-induced lung injury the relation between the 
local dose and FDG uptake response may play an important role. Guerrero et al. (44) performed 
restaging 
18
F-FDG PET-CT between 4 and 12 weeks after radiotherapy of 36 esophageal cancer 
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patients. The authors looked for a relationship between the local radiation dose and post-
treatment FDG uptake in the lung. The average FDG uptake in the lung versus radiation dose 
was obtained for each patient and a linear relationship was found. McCurdy et al. (45) quantified 
the post radiotherapy FDG pulmonary uptake dose response in lung cancer patients. 24 lung 
cancer patients received restaging 
18
F-FDG PET-CT approximately 6 weeks after completion of 
chemo-radiotherapy. In 22 patients, a positive linear relationship was found between the local 
radiation dose and the voxel-averaged post-treatment FDG uptake. Authors normalized the SUV 
in the irradiated lung to that in the un-irradiated lung and suggested that the slope of the 
regression is the pulmonary metabolic radiation response (PMRR). In our results a linear 
relationship was found between the local radiation dose and both mid-therapy and post-therapy 
FDG uptake in the lung. The slope of this relationship varied across the patients and could be 
reflecting the range of underlying biologic response to radiation. The individual slope 
(sensitivity) could be a measure of underlying intensity of lung injury (Figure 32). At mid-
therapy, a positive linear relationship was found for 17 patients (patients 3 and 21 had negative 
slopes with values of –0.0008 and –0.005, respectively). At post-therapy, 6 patients have had a 
positive linear relationship (patient 21 had a negative slope with a value of –0.0025). This 
positive correlation between radiation dose and lung FDG uptake could result from radiation 
pneumonitis. Radiation pneumonitis is an inflammatory reaction which is characterized by 
rapidly resolving vascular changes. Radiation pneumonitis may happen within irradiated lung 
tissue in response to injury (46) and inflammatory cells have been reported to take up more FDG 
than normal cells (47). 
Another possibility for the increased FDG uptake with dose could be the presence of lung 
fibrosis. RT dose induced fibrosis (48) and a fibrotic area increases the uptake of FDG (49). 
Fibrosis is defined by hardening or overgrowth of the lung tissue and is associated with abnormal 
interstitial accumulation of extracellular matrix proteins. It is usually the end result of chronic 
pneumonitis. On the other hand, it has recently been suggested that an increase in lung 
parenchymal vasculature (due to angiogenesis) in fibrotic areas results in an increased FDG 
uptake rather than up-regulation of the metabolic rate in fibrotic cells (50).  
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The slope of the linear dose FDG relationship mid-therapy and post-therapy are very similar 
(Figure 31). This implies that the increase in the FDG-uptake per dose post-therapy compared to 
mid-therapy for most of the patients is equal. However, there was a significant increase (15%) in 
the intercept of the linear relationship from mid-therapy to post-therapy. This implies that 
irradiation of healthy lung (by delivery of maximum 15 Gy) induced a general elevation in FDG 
activity in the lungs six weeks after the end of radiotherapy. This “additive effect”, on average, 
was constant for all dose levels. 
5.4.3. Influence of Tarceva 
No articles were found reporting on the effect of Tarceva on lung FDG uptake. In our data no 
significant differences were found in the lung SUVmedian between Tarceva and non-Tarceva 
groups of patients at each session. However, by looking at the FDG uptake response versus RT 
dose graphs for Tarceva and non-Tarceva groups, a linear relationship was found between the 
local radiation dose and mid-therapy FDG uptake in both groups. Both groups had the same 
slope, which implies that Tarceva does not affect the FDG uptake per radiation dose at this 
session. Nevertheless, there was a significant increase (16%) observed in the intercept for 
patients receiving Tarceva. This implies that Tarceva increase the general FDG uptake level in 
the healthy lung compared to radiation. Comparing the two groups in the post-therapy session, 
larger differences could be seen. The slope for the Tarceva group decreased by 70% compared to 
the non-Tarceva group, while the intercept increased by 120%. In other words, Tarceva 
administration results in lower sensitivity to dose; any dose levels will result in an identically 
high SUV. One way to interpret these trends is to consider that Tarceva acts in the same manner 
as radiation, but has an equal effect on all regions in the lung. Already after 5 days elevated SUV 
levels may be observed, but RT dose-response is also obtained. However, if Tarceva further 
administered, the glucose uptake in the lung is saturated and the radiation dose has no effect. In 
this case, any radiation dose level will result in an identical SUV level, as indeed was observed. 
5.4.4. Time trend in HU 
A dose-dependent increase lung density after RT has been reported after analyzing individual 
dose response curves of patients examined by either CT (51) (52) (53) (54) or routine chest x-
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rays (55) post RT. Between 1978 and 1982, 329 breast cancer patients received post-mastectomy 
radiotherapy at the Department of Oncology, University Hospital of Aarhus, Denmark (55). 
Patients were irradiated with a minimum target dose of 36.6-40.92 Gy (12 fractions, 2 fractions 
per week and 22 fractions, 5 fractions per week, respectively). 207 of these patients had pre-
treatment radiographs and at least three post-treatment radiographs. It was reported that the 
average lung density was significantly increased in the radiation field within a few weeks after 
radiotherapy (and up to 6 months after radiotherapy). From our data, no significant changes were 
found in HUmedian between various sessions. 
5.4.5. Density dose response 
In this section, we studied the relationships between RT dose and the changes in regional lung 
CT number. Other than exploring FDG uptake response versus RT dose, changes in lung tissue 
density assessed with CT could also be important when assessing RT-induced lung injury. 
Levinson et al. (52), evaluated changes in lung tissue density in 13 patients with lung cancer. CT 
scans were performed prior to RT. Follow-up CT scans were performed at various intervals 
following RT (at 3, 6, and 12 months). The data suggest that the CT density increased markedly 
with dose by comparing post-treatment scans and pre-treatment scans. Jinli et al. (54) studied the 
temporal nature of regional lung density changes in 118 patients who received external beam RT. 
CT scans were performed before and after radiotherapy. Patients with different cancers received 
target doses up to a total dose of 73.6 Gy, with a fraction size between 1.25 Gy and 2 Gy. They 
observed that the lung density increased within 6 months after RT, and thereafter was stabilized. 
We measured lung density changes as a function of RT dose using voxel-by-voxel dose response 
analysis. Our result showed that there is a linear relationship between lung density and local RT 
dose during and after RT. It has been reported that lung density changes reflect both pneumonitis 
(56) and fibrosis (57) in the irradiated area of the lung, which indicates that these are 
pathological processes taking place in our patient cohort as well. Furthermore, a significant 
increase (135%) in the slope from mid-to post-therapy was observed. In other words, RT dose 
had a “multiplicative effect” on lung density. This may imply that lung tissue physical density 
changes correlated with pneumonitis and fibrosis incidence, and they increase with increasing 
RT dose level.  
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5.4.6. The effect of lung density on SUV 
Another path to explore was to determine if lung’s density changes with dose was responsible for 
the observed trends in lung SUV. From our results, increased dose gave increased lung density, 
and higher density could explain the increase in SUV. We tried to separate the effect of dose on 
density from the effect of dose on SUV by doing the following analysis. First, a graph was 
generated showing the relation between mean SUV and mean HU in given dose bins (Figure 54). 
The correlation between SUV and HU was 0.78 and 0.67 at mid and post-treatment, respectively. 
It is clear that a higher SUV is found in regions of the lung with higher HU.  
In Figure 55, we made a correction for this slight increase in density by introducing another 
measure, SUVCORR = –SUV1000/HU. Using this measure to compensate for the effect of 
increased density, we can still see that corrected SUV in post therapy had an increase in slope 
compared with the mid-therapy session. Furthermore, the SUV levels in post-therapy were 
elevated from the SUV levels in mid-therapy. 
This may suggest that the change in FDG response versus dose was not entirely attributable to 
the changes in the lung’s density. The trend from mid-therapy to post-therapy was observable 
even though we compensate for the effect of changes in density.  
 
Figure 54: Correlation between lung HU and SUV. 
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Figure 55: lung FDG uptake response (corrected for density) versus percentage delivered dose 
plotted for mid-therapy and post-therapy session. 
5.5. Esophagus 
The majority of reports about radiation induced esophagitis using 
18
F-FDG PET-CT are from 
esophageal cancer patients. However, thoracic radiation therapy in patient with NSCLC can 
cause esophagitis. It is a common complication of such patients and a source of considerable 
morbidity. 
5.5.1. Time trend in SUV 
Bhargava et al. (58) performed post-therapy 
18
F-FDG PET-CT scan on a patient with NSCLC. 
The PET images showed FDG uptake in the region of radiation-induced esophagitis. Yuan et al. 
(59) studied changes in esophageal FDG activity with time (from pre-RT to during-RT after 
delivery of 45 Gy) in fifty patients with NSCLC (stage I to III). All patients received more than 
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60 Gy RT dose. Authors found that esophageal NSUV
19
 at the tumor level increased 
significantly during radiation therapy. 
No significant differences in FGD uptake is found between sessions in esophagus. Similar to 
what we did for lung, we also extracted SUV90 from V10 and V20 for esophagus for all patients in 
three sessions. The results showed no significant difference between sessions. 
5.5.2. FDG uptake response versus dose  
Nijkamp et al. (60) investigated a correlation between RT dose and acute esophagitis using FDG 
PET scans acquired within 3 months after concurrent chemo-radiotherapy. Eighty-two NSCLC 
patients treated with 24  2.75 Gy included in the study. They reported that the dose levels 
higher than 55 Gy on the esophagus were indicative for increased FDG uptake. 
In our study a linear relationship was found between the local radiation dose and both mid-
therapy and post-therapy FDG uptakes in esophagus. This correlation between RT dose and FDG 
uptake could reflect acute esophagitis. Acute esophagitis is inflammation of esophagus and 
usually occurs in patients who have undergone thoracal radiotherapy within 90 days after 
initiation of radiation-therapy (61). 
No significant changes were found in slope and intercept of this linear regression from mid-
therapy to post-therapy sessions. This may reflect that esophagitis remained stable in time (from 
mid-therapy to post-therapy session). 
5.6. Heart 
Myocardium was known to be a relatively radiation resistant before the 1960’. Recently, 
however, many researchers reported that radiation induced myocardial damages in the late phase 
were happened to the patient receiving thoracic irradiation (62) (63).  
                                                 
19
  NSUV= SUVmax of ROI/ mean SUV of the aortic arch 
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5.6.1. Time trend in SUV 
Jingu et al. (64) performed 
18
F-FDG PET-CT scan on esophageal cancer patients treated with 
radiation therapy (median prescribed dose of 60 Gy, daily fraction dose of 2 Gy, 5 days a week). 
The examination was done at least 3 months after the completion of chemo-radiotherapy (median 
of 9.25 months). Authors reported that 13 of the 64 patients have shown high FDG uptake in the 
basal myocardium (comparing median of the myocardium SUVmax inside and outside of the 
irradiated fields). This finding might indicate radiation induced myocardial damage. 
In contrast, Konski et al. (65) performed pre- and post-treatment 
18
F-FDG PET-CT on 53 
advanced esophageal cancer patients who received thoracic radiotherapy (median prescription 
dose of 50.4 Gy, raction size of 1.8 Gy). The post-treatment examination was performed 4-6 
weeks after the end of the treatment and no correlation was found between changes myocardial 
SUVmax and cardiac toxicity. 
We did not found any significant differences in the heart SUVmedian (Figure 30) and SUVmax (data 
not shown) between sessions. As mentioned before, many articles report cardiac toxicity as a late 
effect of radiation. This suggests that the time window of six weeks after treatment is too small 
to see any changes in the heart’s FDG uptake. 
Moreover, researchers investigated the impact of heart co-irradiation on the radiation 
pneumonitis both in animals and humans. Experimental studies in animal models have shown 
heart exposure can influence the occurrence of RILT and thus it is important to prevent 
irradiating the heart when treating thoracic cancers (66). It has been reported that in patients with 
NSCLC, irradiation of the heart could enhance the risk of RILT (67). Thus avoiding cardiac 
irradiation could reduce the risk of RILT. 
5.6.2. FDG uptake response versus dose  
No articles were found to assess glycolytic activity dose response in irradiated heart for patients 
with thoracic cancer. Studying heart, a positive correlation is found between RT dose and FDG 
uptake in mid-therapy, while in post-therapy session the correlation between RD dose and FDG 
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is negative. This could imply that, for positive correlations in mid-therapy, a transient 
inflammation or cellular stress had occurred in the heart.  
5.7. Bone marrow 
Bone marrow is very sensitive to radiation because bone marrow cells are dividing rapidly. 
Damaging in bone marrow can lead to lower levels of platelets, white blood cells, and red blood 
cells. Accordingly, bone marrow in the spinal area is another organ to be considered for radiation 
toxicity when thoracic radiotherapy as a treatment for NSCLC is used. 
5.7.1. Time trend in SUV 
Kenser et al. (68) performed 
18
F-FDG PET-CT scan in mice normal tissues during the 2 months 
of radiation. Four mice received 12 Gy in a single fraction to the left half of the body. Authors 
reported a decrease in femoral bone marrow FDG uptake (particularly between days 2 and 8) in 
the irradiated part of the body compared to the non-irradiated part. 
The bone marrow resides in the trabecular spaces in the bone. Accordingly, the delineated area 
for bone marrow consists of both the marrow and bone. The calculated SUV for this area is in 
fact the SUV for such a mix. 
In our study we did not find any significant changes in bone marrow FDG uptake in various 
sessions. Bone marrow SUV90 from V10 and V20 was extracted for all patients in three sessions. 
The results showed no significant difference between sessions. 
5.7.2. FDG uptake response versus dose  
No articles were found reporting the FDG uptake response in bone marrow against RT dose. In 
our study, a negative linear relationship was found between the local radiation dose and both 
mid-therapy and post-therapy FDG uptake in bone marrow. This negative correlation may imply 
that radiation sterilized some cells and inhibiting their ability to divide. Furthermore, a number of 
cells which received relatively high dose degenerated and died at the very first post-irradiation 
mitosis. After six weeks of radiation therapy this linear relationship decreased towards the lower 
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SUV levels. We speculated that at post-therapy, where twice as RT dose in mid-therapy was 
delivered, even though some of the cells repaired, more cells were sterilized. In addition, those 
cells that successfully repaired and underwent couple of divisions by delivery of 15Gy in mid-
therapy, died after delivery of 30Gy. In other words, the number of sterilized or dead cells 
correlated with both high RT dose region in the bone marrow and the total amount of dose 
delivered. 
5.8. Influence of Tarceva on orangs at risk 
No significant differences were found in esophagus, heart, and bone marrow SUVmedian between 
Tarceva receiving and non-Tarceva receiving groups of patients in each session. No useful 
results were achieved by separating patients to Tarceva and non-Tarceva groups and by 
analyzing esophagus and heart FDG uptake response versus dose at mid- and post-therapy (data 
not shown).  
By comparing bone marrow FDG uptake response versus RT dose in post-therapy for patients 
who received Tarceva and for patients who didn’t, the additive effect was observed in Tarceva 
receiving patients (Figure 47). This elevation in FDG uptake in Tarceva receiving patients could 
suggest that bone marrow stimulates Tarceva drug six weeks after completion of treatment. 
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6. Conclusion  
The computer code developed for this work co-registers the planning CT, a series of PET-CT 
scans, and the RT dose. This program has been tested and debugged in a number of occasions 
and can be regarded as a reasonably well-working piece of software. It can also be used as a test 
and analysis platform by other researchers, and can be extended to be used in other similar 
studies. 
 
The tumor’s metabolic response and the FDG uptake before initiation of radiotherapy varied 
from patient to patient. Moreover, the FDG change from session to session was not identical for 
individual patients. However, this study has shown a significant reduction of tumor FDG activity 
(in SUVmax) in patients with NSCLC six weeks after fractionated radiotherapy.  
 
Studying the SUV levels in healthy organs, it is concluded that the metabolic changes during 
radiotherapy does not have a significant relationship with the metabolic activity after treatment. 
Furthermore, the FDG uptake and radiotherapy dose at mid- and post-therapy in organs at risk 
revealed a significant linear dose-response relationship. A relationship between lung density and 
dose was also identified in both sessions from the CT images. After accounting for increased 
density in the lung, our conclusions about the relationship between dose and FDG uptake (a 
significant linear relationship) still remains valid.  
 
This study also investigated the effect of Tarceva on FDG uptake of the tumor and healthy 
organs. The results show that this drug has minimal effect on the FDG uptake of tumor. 
However, the effect of Tarceva on the lungs was clearly observable. 
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7. Further Work 
This work could benefit from extensions in a number of ways. For example, while in this work 
we used a single delineation from planning CT, it is also possible to further refine the analysis by 
having tumors delineated at all available sessions. This could provide us with a more accurate 
view of how FDG uptake changes in tumors during radiotherapy. Explicitly, we could see how 
the FDG uptake changes if patients indeed have tumor shrinkage or growth. Having such results 
from PET investigations, we could compare those with clinical outcome such as survival time. 
Moreover, with such a comparison we may be able to find the optimal timing for assessing local 
control using 
18
F-FDG PET-CT scans. 
Another extension of this work would be to separate various volumes in the lung, since different 
areas within the lung have different sensitivity to radiation. Such a refined delineation effort 
combined with study of the FDG uptake will help us understand the areas that are more sensitive 
to radiation. Later, we could arrange for a better treatment plan by reducing the exposure of these 
areas. 
It has been reported in a preclinical study that heart irradiation results in increasing end-diastolic 
pressure and can promote pulmonary interstitial edema (69). Having patient’s blood pressure 
measured before each session can help us to further investigate the correlation between blood 
pressure and heart FDG uptake. Furthermore, a preclinical study suggests that the breathing rate 
(BR) can be a surrogate measure of radiation pneumonitis (70). Accordingly, measuring BR 
before each session will also provide us with insight to understand RILT further. In addition if 
data about dyspnea grading for patients is gathered, it could help us further in understanding 
RILT. 
Inflammation in the lung can be described as the accumulation of fluid, plasma proteins, and 
white blood cells. This phenomenon is generally marked by increased levels of cytokines (71). 
Cytokines are small proteins and are released by a broad range of cells, including immune cells. 
Accordingly, cytokine analysis can identify the presence of an activated immune response. 
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Analyzing blood samples for cytokines could help us identify the correlation between FDG 
uptake and inflammation as an outcome.  
Epidermal growth factor receptor (EGFR) inhibitor treatment is associated with the development 
of dermatologic side effects (72). Skin toxicity such as skin rash is a common side effect in 
Tarceva-treated patients with advanced or metastatic non-small cell lung cancer (73). Such side 
effects can have an impact on a patient’s quality of life. Thus skin toxicity grading could be 
valuable in order to search for correlation between degree of toxicity of skin and clinical 
outcome. Adapting Tarceva dose according to skin toxicity grade could improve a patient’s 
quality of life. 
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9. Appendix A 
 
Figure 56: Anatomy of the lung 
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10. Appendix B 
Table 6: Critical values of the Mann-Whitney U-test.  n1 and n2 represent the number of elements 
in sample 1 and 2. U value required to reach the 5% of significance. 
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Table 7: Statistical U-values for man-Whitney U-test comparing sessions (N1=14, N2=19, N3=7) 
Organ 
U value 
(pre- therapy 
 vs.  
mid-therapy) 
U value 
(pre-therapy  
vs.  
post-therapy) 
U value 
(mid-therapy  
vs. 
 post-therapy) 
GTVmax 119 21 115 
GTVmean 136 35 95 
Heartmedian 130 54 82 
Esophagusmedian 174 69 65 
Bone marrowmedian 192 73 89 
Ipsilateral lungmedian 156 66 65 
Contralateral lungmedian 126 55 52 
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Table 8: statistical U-values for Mann-Whitney U-test (p=0.05) comparing Tarceva and non-
Tarceva group (Ntarceva=10, Nnon-tarceva=9) 
Organ 
NSUV± SE (mid-therapy) 
U value (Tarceva and non-
Tarceva group) 
Non-Tarceva Tarceva 
GTVmax 0.9±0.1 1.1±0.2 33 
GTVmean 0.8±0.1 1.0±0.1 32 
Heartmedian 0.9±0.1 1.1±0.1 24 
Esophagusmedian  1.1±0.1 1.3±0.1 29 
Bone marrowmedian 1.1±0.1 1.2±0.1 36 
Ipsilateral lungmedian 0.9±0.1 1.2±0.2 34 
Contralateral lungmedian 1.1±0.1 1.2±0.1 28 
Lungmedian 1.0±0.1 1.2±0.1 120 
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11. Appendix C 
Some of the main codes developed for this study are represented here. 
;%%%%%%%%%%%%%%%%%%%%%%Main routines%%%%%%%%%%%%%%%%%%%%%%%%%% 
ref_res=[3.0,3.0,3.0] 
i = '' 
READ, i, PROMPT='patient name: ' 
 
file = FILEPATH('PAT'+i, ROOT_DIR='C:', SUBDIRECTORY='THORAT') 
 j='' 
 READ, j, PROMPT='session: ' 
 path=file+('\PAT'+i+'PET'+j) 
 
ct_cat=path+'\ACCT' 
CT, ct_cat, ref_res, ct_image, ct_res, ct_pos 
 
rct_cat=file+('\PAT'+i+'RT'+'\CT') 
CT,  rct_cat, ref_res, rct_image, rct_res, rct_pos 
 
ct_rct, ct_image, rct_image, ct_res,  rct_res, shif_xyz, ct_mod 
d_cat=file+('\PAT'+i+'RT') 
RT, d_cat,ref_res, rct_res, d_pos, d_image 
 
 weight='' 
 READ, weight, PROMPT='weight: ' 
im_ses=j 
pt_cat=path+'\PET' 
PET, pt_cat, ref_res, pt_res, pt_image, pt_pos,weight 
slice=80 
rct_d,slice, ref_res, rct_image, d_image, rct_pos, d_pos, d_mod 
rct_pt,pt_pos,ct_pos,ref_res, slice, rct_image,pt_image, shif_xyz, pt_mod,ct_mod 
file_mkdir, file+'\RESULTS' 
cd, file+'\RESULTS' 
;save, filename='D_recon.sav', d_mod 
;save, filename='CT_recon'+im_ses+'.sav', ct_mod 
;save, filename='RCT_recon.sav', rct_image 
;save, filename='PET_recon'+im_ses+'.sav', pt_mod 
;ANALYSIS, file, im_ses 
End 
 
;%%%%%%%%%%%%%%%Reading and displaying planning CT and CT series%%%%%%%%%%%%%%% 
 
pro CT, ct_cat, ref_res, ct_image, ct_res, ct_pos 
 
obj= OBJ_NEW('IDLffDICOM') 
cd, ct_cat 
files= FILE_SEARCH ('*', count= nct) 
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read=obj->Read(files(0)) 
 
dim_x=obj->getvalue('0028'x, '0011'x,/no_copy) 
dim_x=*dim_x(0) 
dim_y=obj->getvalue('0028'x, '0010'x,/no_copy) 
dim_y=*dim_y(0) 
dim_z=nct 
 
ct_pos=obj->getvalue('0020'x, '0032'x,/no_copy) 
ct_pos=*ct_pos(0) 
ct_pos = float(STRSPLIT(ct_pos,'\', /EXTRACT ) ) 
 
ct_res = obj->getvalue('0028'x, '0030'x,/no_copy) 
ct_res=*ct_res(0) 
ct_res = float(STRSPLIT(ct_res,'\', /EXTRACT ) ) 
 
 
img=obj->getvalue('7FE0'x, '0010'x,/no_copy) 
img=*img(0) 
 
new=fltarr(nct) 
for k=0, nct-1 do begin 
 read=obj->Read(files(k)) 
 ct_pos=obj->getvalue('0020'x, '0032'x,/no_copy) 
 ct_pos=*ct_pos(0) 
 ct_pos = float(STRSPLIT(ct_pos,'\', /EXTRACT ) ) 
 
    new(k)=ct_pos(2) 
endfor 
 
ind_sort=sort(new) 
sorted=new[sort(new)] 
 
res_z=abs(sorted(2)-sorted(1)) 
ct_res=[ct_res(0), ct_res(1), res_z] 
 
img_3d=fltarr(dim_x,dim_y,dim_z) 
for i=dim_z-1, 0, -1 do begin 
 ind=ind_sort(i) 
 
 read=obj->Read(files(ind)) 
 img=obj->getvalue('7FE0'x, '0010'x,/no_copy) 
 ct_pos=obj->getvalue('0020'x, '0032'x,/no_copy) 
 ct_pos=*ct_pos(0) 
 ct_pos = float(STRSPLIT(ct_pos,'\', /EXTRACT ) ) 
 img=*img(0) 
 img_3d(*,*, i)=img 
 
endfor 
 
ct_image=img_3d 
 
ct_image(where(ct_image le 0))=0 
cf=ct_res*[dim_x, dim_y, dim_z]/ref_res 
CT_image=congrid(CT_image, cf(0), cf(1), cf(2), /CENTER) 
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help,'dim=',img_3d 
print, 'pos=',ct_pos 
print,'res=',ct_res 
 
 
; We only want to match bone 
 
ct_congrid(where(ct_congrid lt 1200))=0 
rct_mod(where(rct_mod lt 1200))=0 
 
;match lungs 
ct_congrid(where(ct_congrid gt 800))=0 
rct_mod(where(rct_mod gt 800))=0 
 
ct_congrid(where(ct_congrid lt 100))=0 
rct_mod(where(rct_mod lt 100))=0 
 
ct_congrid(where(ct_congrid))=1 
rct_mod(where(rct_mod))=1 
end 
;%%%%%%%%%%%%%%%%%%Co-registragion of CT series and planning CT%%%%%%%%%% 
;resolution=[3,3,3] for both rct_image and ct_image. 
;define ct_mod as an array with dim_x and dim_y equal to rct_image (crop edges). 
;define rct_mod as an array with dim_z equal to ct_image. 
;now ct_mod and rct_mod have the same dimentions, which is:[ dim_rct(0),dim_rct(1),dim_ct(2)]. 
;corr between rct_mod and ct_mod. 
;use shif_xyz to shift the ct_mod on top of the rct_mod and cut unreqiured regions.. 
;ct_mod now has the same dimentions as original rct_image. 
;PATIENT NUMBER 11 SESSION 2: different position of the arms!. 
 
pro ct_rct, ct_image, rct_image, ct_res,  rct_res, shif_xyz, ct_mod 
 
dim_rct=(size(rct_image))[1:3] 
dim_ct=(size(ct_image))[1:3] 
 
ct_mod=intarr(dim_rct(0),dim_rct(1),dim_ct(2)) 
 
xs=( dim_ct(0)-dim_rct(0))/2 
ys=( dim_ct(1)-dim_rct(1))/2 
 
ct_mod=ct_image(xs:xs+dim_rct(0)-1,ys:ys+dim_rct(1)-1,*) 
 
rct_mod=intarr(dim_rct(0),dim_rct(1),dim_ct(2)) 
rct_mod(*,*, 0:dim_rct(2)-1)=rct_image 
 
correl=corr(rct_mod,ct_mod) 
shif=where(correl eq max(correl)) 
shif_xyz=array_indices(correl, shif) 
 
 
if abs(shif_xyz(0)) gt dim_rct(0)/2 then shif_xyz(0)=-(dim_rct(0)-shif_xyz(0)) 
if abs(shif_xyz(1)) gt dim_rct(1)/2 then shif_xyz(1)=-(dim_rct(1)-shif_xyz(1)) 
if abs(shif_xyz(2)) gt dim_ct(2)/2 then shif_xyz(2)=(dim_ct(2)-shif_xyz(2)) 
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ct_mod=shift(ct_mod, shif_xyz(0) , shif_xyz(1), 0) 
ct_mod=ct_mod(*,*,shif_xyz(2):shif_xyz(2)+dim_rct(2) -1) 
 
rct_mod=rct_mod(*,*,0:dim_rct(2)-1) 
rct_image=rct_mod & rct_mod=0 
end 
;%%%%%%%%%%%%%%%%%%% reading and displaying RT dose%%%%%%%%%%%%%%%% 
 
PRO RT, d_cat,ref_res, rct_res, d_pos, d_image 
 
obj= OBJ_NEW('IDLffDICOM') 
cd, d_cat 
files= FILE_SEARCH ('RD*', count= nd) 
 
read=obj->Read(files(1)) 
 
dim_x=obj->getvalue('0028'x, '0011'x,/no_copy) 
dim_x=*dim_x(0) 
dim_y=obj->getvalue('0028'x, '0010'x,/no_copy) 
dim_y=*dim_y(0) 
 
d_pos=obj->getvalue('0020'x, '0032'x,/no_copy) 
d_pos=*d_pos(0) 
 
d_pos = float(STRSPLIT(d_pos,'\', /EXTRACT ) ) 
 
d_res = obj->getvalue('0028'x, '0030'x,/no_copy) 
d_res=*d_res(0) 
 
 
img=obj->getvalue('7FE0'x, '0010'x,/no_copy) 
dim_z=(size(img))[1] 
 
 
img_3d=fltarr(dim_x,dim_y,dim_z) 
 
for k=0, nd-1 do begin 
 read=obj->Read(files(K)) 
 img=obj->getvalue('7FE0'x, '0010'x,/no_copy) 
 dgs=obj->getvalue('3004'x, '000E'x,/no_copy) 
 dgs=*dgs(0) 
 
 j=0 
  for i=0, dim_z-1 do begin 
  imag=float(*img(i)) 
  img_3d(*,*, j)=img_3d(*,*, i)+(imag*dgs)       
 
  j=j+1 
 endfor 
endfor 
 
d_res = [(float(STRSPLIT(d_res,'\', /EXTRACT )))[0], (float(STRSPLIT(d_res,'\', /EXTRACT )))[1],rct_res(2)] 
 
d_image=img_3d 
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cf=d_res*[dim_x, dim_y, dim_z]/ref_res 
d_image=congrid(d_image, cf(0), cf(1), cf(2), /CENTER) 
end 
;%%%%%%%%%%%%%%%%%%%%% Co-registration of RT dose and planning CT%%%%%%%%%%% 
 
;d_mod is d_image which is shifted along x and y directions 
PRO rct_d, slice, ref_res, rct_image, d_image, rct_pos, d_pos, d_mod 
 
dim_rct=(size(rct_image))[1:3] 
dim_d=(size(d_image))[1:3] 
;change dim_rct(0) to dim_d(0) 
d_image=congrid(d_image, dim_d(0), dim_d(1), dim_rct(2),/center) 
 
d_mod=rct_image*0.0 
;add diff(0) 
diff=[round((d_pos(0)-rct_pos(0))/ref_res(0)),round((d_pos(1)-rct_pos(1))/ref_res(1))] 
 
; for some patients dim_d(1) is greater than dim_rct(0), ex. patient number 4. 
for i=0, 2 do begin 
 if dim_d(i) ge dim_rct(i) then begin 
    dim_d(i)=dim_rct(i) 
 endif 
endfor 
;replace * with (0:dim_d(0)-1) 
d_mod(0:dim_d(0)-1, 0:dim_d(1)-1, *)=d_image(0:dim_d(0)-1, 0:dim_d(1)-1, *) 
;replace 0 with diff(0) 
d_mod=shift(d_mod, diff(0), diff(1), 0) 
 
 
test=(d_mod/max(d_mod))+(rct_image/2048.) 
 
window,0, xsize=500, ysize=500 
tvscl, congrid(test(*, *, 75), 500, 500) 
 
 
 
;%%%%%%%%%%%%%%%%%%COLOR-BLENDING%%%%%%%%%%%%%%%%%%%%% 
 
d_min=1 
d_max=30 
 
LOADCT, 4 
TVLCT, red, green, blue, /GET 
 
image_d = BYTARR(3, dim_rct(0), dim_rct(1)) 
image_d(0,*,*) = red(bytscl(d_mod(*,*,slice), min=d_min, max=d_max)) 
image_d(1,*,*) = green(bytscl(d_mod(*,*,slice), min=d_min, max=d_max)) 
image_d(2,*,*) = blue(bytscl(d_mod(*,*,slice), min=d_min, max=d_max)) 
 
ct_min=700 
ct_max=1300 
LOADCT, 0 
TVLCT, red, green, blue, /GET 
image_CT =BYTARR(3, dim_rct(0), dim_rct(1)) 
image_CT(0,*,*) = red(bytscl(rct_image(*,*,slice), min=ct_min, max=ct_max)) 
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image_CT(1,*,*) = green(bytscl(rct_image(*,*,slice), min=ct_min, max=ct_max)) 
image_CT(2,*,*) = blue(bytscl(rct_image(*,*,slice), min=ct_min, max=ct_max)) 
 
 blending av PET-CT skjer via alpha-faktor 
alpha=0.6 
image_fus = byte(alpha*float(image_CT)+(1.0-alpha)*float(image_d)) 
image_fus=congrid(image_fus,3,dim_rct(0)*3,dim_rct(1)*3,/center) 
window, 4, xsize=dim_rct(0)*3, ysize=dim_rct(1)*3 
tv, image_fus, true=1 
End 
 
;%%%%%%%%%%%%%%%%%% Coregistration of planning CT and PET series%%%%%%%%%%%%%% 
 
resolution=[3,3,3] for both rct_image and pt_image_mod. 
define pt_mod as an array with dim_x and dim_y equal to rct_image. (crop edges) 
use shif_xyz to shift the pt_mod on top of the rct_mod and cut unreqiured regions.. 
pt_mod now has the same dimentions as original rct_image. 
PT_MOD_NEW IS MODIFED SHIFTE PT IMAGES. THE MOST TRUSTABLE!!!! 
 
PRO rct_pt,pt_pos,ct_pos,ref_res, slice, rct_image,pt_image, shif_xyz,pt_mod,ct_mod 
rct_image=ct_mod 
working with pt_image_mod instead of pt_image. 
dim_rct=(size(rct_image))[1:3] 
dim_pt=(size(pt_image))[1:3] 
 
pt_mod_new=intarr(dim_rct(0),dim_rct(1),dim_pt(2)) 
 
xs=( dim_pt(0)-dim_rct(0))/2 
ys=( dim_pt(1)-dim_rct(1))/2 
 
pt_mod_new=pt_image(xs:xs+dim_rct(0)-1,ys:ys+dim_rct(1)-1,*) 
 
diff=round(-(pt_pos-ct_pos)/ref_res) 
pt_mod_new=shift(pt_mod_new, diff(0), diff(1),diff(2)) 
 
pt_mod_new=shift(pt_mod_new, shif_xyz(0) , shif_xyz(1), 0) 
pt_mod_new=pt_mod_new(*,*,shif_xyz(2):shif_xyz(2)+dim_rct(2) -1) 
window, 2, xsize=dim_rct(0), ysize=dim_rct(1) 
tvscl,(pt_mod_new(*,100,*)/max(pt_mod_new)+rct_image(*,100,*)/2048) 
window,3, xsize=dim_rct(0), ysize=dim_rct(1) 
tvscl,(pt_mod_new(100,*,*)/max(pt_mod_new)+rct_image(100,*,*)/2048) 
%%%%%%%%%%%%%%%%%%COLOR-BLENDING-CORONAL 
SLICE%%%%%%%%%%%%%%%%%%%%% 
PET_min=0.5 
PET_max=2 
LOADCT, 4 
TVLCT, red, green, blue, /GET 
slice=100 
 
image_pt = BYTARR(3, dim_rct(1), dim_rct(2)) 
image_pt(0,*,*) = red(bytscl(pt_mod_new(*,slice,*), min=PET_min, max=PET_max)) 
image_pt(1,*,*) = green(bytscl(pt_mod_new(*,slice,*), min=PET_min, max=PET_max)) 
image_pt(2,*,*) = blue(bytscl(pt_mod_new(*,slice,*), min=PET_min, max=PET_max)) 
 
ct_min=700 
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ct_max=1300 
LOADCT, 0 
TVLCT, red, green, blue, /GET 
image_CT =BYTARR(3, dim_rct(1), dim_rct(2)) 
image_CT(0,*,*) = red(bytscl(rct_image(*,slice,*), min=ct_min, max=ct_max)) 
image_CT(1,*,*) = green(bytscl(rct_image(*,slice,*), min=ct_min, max=ct_max)) 
image_CT(2,*,*) = blue(bytscl(rct_image(*,slice,*), min=ct_min, max=ct_max)) 
 
 blending av PET-CT skjer via alpha-faktor 
alpha=0.6 
image_fus = byte(alpha*float(image_CT)+(1.0-alpha)*float(image_pt)) 
image_fus=congrid(image_fus,3,dim_rct(0)*2,dim_rct(1)*2,/center) 
window, 1, xsize=dim_rct(0)*3, ysize=dim_rct(2)*3 
tv, image_fus, true=1 
;%%%%%%%%%%%%%%%%%%COLOR-BLENDING-SAGGITAL SLICE%%%%%%%%%%%%%%%%% 
 
PET_min=0.5 
PET_max=2 
 
LOADCT, 4 
TVLCT, red, green, blue, /GET 
slice=100 
image_pt = BYTARR(3, dim_rct(1), dim_rct(2)) 
image_pt(0,*,*) = red(bytscl(pt_mod_new(slice,*,*), min=PET_min, max=PET_max)) 
image_pt(1,*,*) = green(bytscl(pt_mod_new(slice,*,*), min=PET_min, max=PET_max)) 
image_pt(2,*,*) = blue(bytscl(pt_mod_new(slice,*,*), min=PET_min, max=PET_max)) 
 
ct_min=700 
ct_max=1300 
LOADCT, 0 
TVLCT, red, green, blue, /GET 
image_CT =BYTARR(3, dim_rct(1), dim_rct(2)) 
image_CT(0,*,*) = red(bytscl(rct_image(slice,*,*), min=ct_min, max=ct_max)) 
image_CT(1,*,*) = green(bytscl(rct_image(slice,*,*), min=ct_min, max=ct_max)) 
image_CT(2,*,*) = blue(bytscl(rct_image(slice,*,*), min=ct_min, max=ct_max)) 
 
 blending av PET-CT skjer via alpha-faktor 
alpha=0.6 
image_fus = byte(alpha*float(image_CT)+(1.0-alpha)*float(image_pt)) 
image_fus=congrid(image_fus,3,dim_rct(0)*3,dim_rct(1)*3,/center) 
window, 2, xsize=dim_rct(0)*3, ysize=dim_rct(2)*3 
tv, image_fus, true=1 
;%%%%%%%%%%%%%%%%%%COLOR-BLENDING-TRANSVERSAL SLICE%%%%%%%%%%%%%% 
 
slice=70 
PET_min=0.5 
PET_max=2 
LOADCT, 4 
TVLCT, red, green, blue, /GET 
image_pt = BYTARR(3, dim_rct(0), dim_rct(1)) 
image_pt(0,*,*) = red(bytscl(pt_mod_new(*,*,slice), min=PET_min, max=PET_max)) 
image_pt(1,*,*) = green(bytscl(pt_mod_new(*,*,slice), min=PET_min, max=PET_max)) 
image_pt(2,*,*) = blue(bytscl(pt_mod_new(*,*,slice), min=PET_min, max=PET_max)) 
 
ct_min=700 
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ct_max=1300 
LOADCT, 0 
TVLCT, red, green, blue, /GET 
image_CT =BYTARR(3, dim_rct(0), dim_rct(1)) 
image_CT(0,*,*) = red(bytscl(rct_image(*,*,slice), min=ct_min, max=ct_max)) 
image_CT(1,*,*) = green(bytscl(rct_image(*,*,slice), min=ct_min, max=ct_max)) 
image_CT(2,*,*) = blue(bytscl(rct_image(*,*,slice), min=ct_min, max=ct_max)) 
 
 
blending av PET-CT skjer via alpha-faktor 
alpha=0.6 
image_fus = byte(alpha*float(image_CT)+(1.0-alpha)*float(image_pt)) 
image_fus=congrid(image_fus,3,dim_rct(0)*3,dim_rct(1)*3) 
 
window,3, xsize=dim_rct(0)*3, ysize=dim_rct(1)*3 
tv, image_fus , true=1 
pt_mod=pt_mod_new 
print,diff 
end 
 
;%%%%%%%%%%%%%%%%%%%%%%Analysis%%%%%%%%%%%%%%%%%%%%%%%%% 
 
PRO ANALYSIS, file, im_ses 
 
slice=70 
ref_res=[3.0,3.0,3.0] 
 
i = '' 
READ, i, PROMPT='patient name: ' 
 
file = FILEPATH('PAT'+i, ROOT_DIR='C:', SUBDIRECTORY='THORAT') 
 
%%%%white background%%%% 
Device, Decomposed=0 ; Index color model. 
LoadCT, 0 ; Normal black to white color table. 
TVLCT, r, g, b, /Get 
TVLCT, Reverse(r), Reverse(g), Reverse(b) 
%%%%%%% 
 
cd, file+'\RESULTS' 
 
ct_files=file_search('CT*', count=nses) 
 
ses=intarr(nses) 
 
for i=0, nses-1 do ses(i)=fix(strmid(ct_files(i), 8, 1)) 
 
restore, ct_files(0) 
 
si=size(ct_mod) 
dim_x=si(1) 
dim_y=si(2) 
dim_z=si(3) 
ct_images=fltarr(dim_x, dim_y, dim_z, nses) 
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ct_images(*,*,*, 0)=ct_mod 
 
for i=1, nses-1 do begin 
 restore, ct_files(i) 
 ct_images(*,*,*, i)= ct_mod 
endfor 
 
for i=0, nses-1 do begin 
 window, i, xsize=3*dim_x, ysize=3*dim_y 
 tvscl, rebin(ct_images(*,*, slice, i),3*dim_x, 3*dim_y, /SAMPLE) 
endfor 
 
rct_file=file_search('RCT*') 
restore,rct_file 
 
d_file=file_search('D*') 
restore,d_file 
 
 
pt_files=file_search('PET*') 
pt_images=fltarr(dim_x, dim_y, dim_z, nses) 
for i=0, nses-1 do begin 
 restore, pt_files(i) 
 pt_images(*,*,*, i)=pt_mod 
 
endfor 
 
struk_file=file_search('struk*') 
restore, struk_file 
 
;%%%%%%%%%%%%%%%%%%%%%%%matchlungs%%%%%%%%%%%%%%%%%%%%%%%%%%% 
index=intarr(dim_x,dim_y,dim_z) 
for i=0, nses-1 do begin 
 ct_1=reform(ct_images(*,*,*,i)) 
 ct_1(where(ct_1 gt 800))=0 
 ct_1(where(ct_1 lt 100))=0 
 ct_1(where(ct_1))=1 
 ;TVSCL,CT_1(*,*,80) 
 index=index+ct_1 
endfor 
 
index(where(index ne nses))=0 
; %%%%%%%%%%%%%%%%%%%%DOSE vs. SUV%%%%%%%%%%%%%%%%%%%%%%%%% 
g= 7 
l= 12 
r= 11 
h= 5 
e= 6 
b= 13 
N=9 
for i=0, nses-1 do begin 
print,i 
pt=reform(pt_images(*,*,*, i)) 
;ctt=reform(ct_images(*,*,*,0)) 
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GTV=reform(struk_new(g, *,*,*)) 
smooth_struc=intarr(5,5,5)+1 
gtv_EXP = DILATE(GTV, smooth_struc) 
 
HEART=reform(struk_new(h, *,*,*)) 
 
smooth_struc=intarr(3,3,3)+1 
heart_EXP = DILATE(heart, smooth_struc) 
 
eso=reform(struk_new(e, *,*,*)) 
ESO=congrid(ESO,dim_x,dim_y,dim_z) 
smooth_struc=intarr(3,3,3)+1 
esoph_EXP = DILATE(eso, smooth_struc) 
 
bone=reform(struk_new(b, *,*,*)) 
BONE=congrid(BONE,dim_x,dim_y,dim_z) 
smooth_struc=intarr(3,3,3)+1 
bone_EXP = DILATE(bone, smooth_struc) 
 
node=reform(struk_new(n, *,*,*)) 
NODE=congrid(NODE,dim_x,dim_y,dim_z) 
smooth_struc=intarr(3,3,3)+1 
node_EXP = DILATE(node, smooth_struc) 
 
struc=reform(struk_new(b, *,*,*)) 
vec=where(struc gt 0  and d_mod gt 10  and gtv_exp ne 1 and heart_exp ne 1 $ 
 And esoph_exp ne 1); and bone_exp ne 1 and index gt 0); and node_exp ne 1) 
me_suv=median(pt(vec)) 
m_suv=prank(pt(vec),90) 
print, 'b_90_10=',m_suv 
;print, 'r_med_10=', me_suv 
struc=reform(struk_new(e, *,*,*)) 
vec=where(struc gt 0  and d_mod gt 10  and gtv_exp ne 1  and heart_exp ne 1 $ 
 and bone_exp ne 1); and node_exp ne 1)and index gt 0  And esoph_exp ne 1 
me_suv=median(pt(vec)) 
m_suv=prank(pt(vec),90) 
print,'e_90_10=', m_suv 
;print,'l_med_10=', me_suv 
struc=reform(struk_new(b, *,*,*)) 
vec=where(struc gt 0  and d_mod gt 20  and gtv_exp ne 1  and heart_exp ne 1 $ 
 And esoph_exp ne 1 ); and bone_exp ne 1  and index gt 0);and node_exp ne 1) 
me_suv=median(pt(vec)) 
m_suv=prank(pt(vec),90) 
print, 'b_90_20=',m_suv 
;print, 'r_med_20=', me_suv 
struc=reform(struk_new(e, *,*,*)) 
vec=where(struc gt 0  and d_mod gt 20  and gtv_exp ne 1 and heart_exp ne 1 $ 
 and bone_exp ne 1); and index gt 0 And esoph_exp ne 1); and node_exp ne 1) 
me_suv=median(pt(vec)) 
m_suv=prank(pt(vec),90) 
print, 'e_90_20=',m_suv 
endfor 
stop 
print, 'l_med_10=', me_suv 
struc=reform(struk_new(e, *,*,*)) 
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vec=where(struc gt 0  and d_mod gt 20  and gtv_exp ne 1  and heart_exp ne 1 $ 
  and bone_exp ne 1 and node_exp ne 1and index gt 0And esoph_exp ne 1) 
me_suv=median(pt(vec)) 
m_suv=mean(pt(vec)) 
 
print, 'e_mn_20=',m_suv 
print, 'e_med_20=', me_suv 
 
struc=reform(struk_new(L, *,*,*)) 
vec=where(struc gt 0  and d_mod gt 20  and gtv_exp ne 1 and index gt 0 and heart_exp ne 1 $ 
 And esoph_exp ne 1 and bone_exp ne 1 and node_exp ne 1) 
me_suv=median(pt(vec)) 
m_suv=mean(pt(vec)) 
print,'l_mn_20=', m_suv 
print,'l_med_20=', me_suv 
 
do_ca=findgen(64)*0.5 
m_d=do_ca*0.0 
m_SUV=do_ca*0.0 
m_ct=do_ca*0.0 
print,'CT' 
for i=1, 63 do begin 
 
 vec=where(struc gt 0  and d_mod le do_ca(i) $ 
 and d_mod gt do_ca(i-1) and gtv_exp ne 1 and index gt 0 and heart_exp ne 1 $ 
 and esoph_exp ne 1 and bone_exp ne 1 and node_exp ne 1) 
 
 if vec(0) ne -1 then begin 
  m_ct(i)=mean(ctt(vec)) 
 
  m_ct(I)=m_ct(I)-1024 
  PRINT,M_ct(I) 
 
 endif else begin 
  m_d(i)=-1 
 endelse 
endfor 
print,'SUV' 
for i=1, 63 do begin 
 
 vec=where(struc gt 0  and d_mod le do_ca(i) $ 
 and d_mod gt do_ca(i-1) and gtv_exp ne 1 and index gt 0 and heart_exp ne 1 $ 
 And esoph_exp ne 1 and bone_exp ne 1 and node_exp ne 1) 
 
 if vec(0) ne -1 then begin 
  m_suv(i)=mean(pt(vec)) 
 
 
  PRINT,M_SUV(I) 
 
 endif else begin 
  m_d(i)=-1 
 endelse 
endfor 
PRINT,'D' 
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for i=1, 63 do begin 
 
 vec=where(struc gt 0  and d_mod le do_ca(i) $ 
 and d_mod gt do_ca(i-1) and gtv_exp ne 1 and index gt 0 and heart_exp ne 1 $ 
 and esoph_exp ne 1 and bone_exp ne 1 and node_exp ne 1) 
 
 if vec(0) ne -1 then begin 
  m_d(i)=mean(d_mod(vec)) 
  PRINT,M_D(I) 
 
 endif else begin 
  m_d(i)=-1 
 endelse 
endfor 
print, roi_name(g),roi_name(l),ROI_NAME(R) 
STOP 
m_d=m_d(where(m_d ne -1)) 
m_suv=m_suv(where(m_d ne -1)) 
 
;%%%%%%%%%%%%%%%%%%%%%%%%%%PLOT%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
window, xsize=1200, ysize=600 
plot, m_d, m_SUV, xtitle='Dose (Gy)',ytitle= 'SUV!Dmean!N',$ 
yrange=[min(m_suv)-0.1,max(m_suv)+0.1],$ 
xtickinterval=2.0,thick=2,xthick=2,ythick=2,charsize=2.5,xstyle=8,ystyle=8.0+1,psym=4,ytickinterval=0.1 
xyouts,1.5,0.4,'Esophagus',charsize=3 
;%%%%%%%%%%%%%%%%%%%%%%% contours%%%%%%%%%%%%%%%%%%%%%%%%% 
 
DEVICE, DECOMPOSED = 0, RETAIN = 2 
LOADCT, 0 
pt=reform(pt_images(*,100,*,1)) 
;GTV=reform(struk_new(14, *,*,80)) 
 
image=reform(struk_new(15, *,100,*)) 
 
; Define the structuring element, apply the 
; morphological operator and display the image. 
radius = 1 
strucElem = SHIFT(DIST(2*radius+1), $ 
   radius, radius) LE radius 
morphImg = MORPH_GRADIENT(image, strucElem) 
;morphImg1 = MORPH_GRADIENT(gtv, strucElem) 
tvs=pt+morphImg 
Tvscl,tvs 
stop 
;%%%%%%%%%%%%%%%%%%%%%%%%%% HISTOGRAM%%%%%%%%%%%%%%%%%%%%% 
pt=reform(pt_images(*,*,*, 1)) 
GTV=reform(struk_new(11, *,*,*)) 
vec_GTV=where(GTV) 
;;%%%%%%% 
FDG_GTV=pt(vec_GTV) 
xmin=min(pt(vec_GTV)) 
xmax=max(pt(vec_GTV)) 
nbin=100 
xspan=xmin+(findgen(nbin)*(xmax-xmin)/(nbin-1)) 
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hist_FDG_GTV=histogram(pt(vec_GTV), nbins=nbin, min=xmin, max=xmax) 
plot, xspan, hist_FDG_GTV2/11334.0,xtitle='SUV',ytitle='Normalized Count', charsize=1.5,linestyle=1, 
psym=10,thick=2 
pt=reform(pt_images(*,*,*, 2)) 
GTV=reform(struk_new(11, *,*,*)) 
vec_GTV=where(GTV) 
;;%%%%%%% 
FDG_GTV=pt(vec_GTV) 
xmin=min(pt(vec_GTV)) 
xmax=max(pt(vec_GTV)) 
nbin=100 
xspan=xmin+(findgen(nbin)*(xmax-xmin)/(nbin-1)) 
hist_FDG_GTV=histogram(pt(vec_GTV), nbins=nbin, min=xmin, max=xmax) 
oplot, xspan, hist_FDG_GTV2/11334.0,linestyle=5, psym=10,thick=2 
pt=reform(pt_images(*,*,*, 0)) 
GTV=reform(struk_new(11, *,*,*)) 
vec_GTV=where(GTV) 
;;%%%%%%% 
FDG_GTV=pt(vec_GTV) 
xmin=min(pt(vec_GTV)) 
xmax=max(pt(vec_GTV)) 
nbin=100 
xspan=xmin+(findgen(nbin)*(xmax-xmin)/(nbin-1)) 
hist_FDG_GTV=histogram(pt(vec_GTV), nbins=nbin, min=xmin, max=xmax) 
oplot, xspan, hist_FDG_GTV2/11334.0,linestyle=0, psym=10,thick=2 
end 
 
;%%%%%%%%%%%%%%%%%%%%%%Extracting data%%%%%%%%%%%%%%%%%%%%%%%% 
print,roi_name 
for k=0, nses-1 do begin 
 
g=8 
h=10 
e=11 
n=9 
r=12 
l=13 
b=14 
 
 
pt=reform(pt_images(*,*,*, k)) 
GTV=reform(struk_new(g, *,*,*)) 
vec_GTV=where(GTV) 
 
print,k+1 
print,roi_name(g) 
print,'min_GTV=',min(pt(vec_GTV)) 
print,'median_GTV=',median(pt(vec_GTV)) 
print, 'mean_GTV=',mean(pt(vec_GTV)) 
print, 'max_GTV=',max(pt(vec_GTV)) 
print,'25_GTV=',prank(pt(vec_GTV),25) 
print,'75_GTV=',prank(pt(vec_GTV),75) 
 
heart=reform(struk_new(h, *,*,*)) 
vec_GTV=where(heart) 
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print,roi_name(h) 
print,'min_heart=',min(pt(vec_GTV)) 
print,'median_heart=',median(pt(vec_GTV)) 
print, 'mean_heart=',mean(pt(vec_GTV)) 
print, 'max_heart=',max(pt(vec_GTV)) 
print,'25_heart=',prank(pt(vec_GTV),25) 
print,'75_heart=',prank(pt(vec_GTV),75) 
 
eso=reform(struk_new(e, *,*,*)) 
vec_GTV=where(eso) 
 
print,roi_name(e) 
print,'min_eso=',min(pt(vec_GTV)) 
print,'median_eso=',median(pt(vec_GTV)) 
print, 'mean_eso=',mean(pt(vec_GTV)) 
print, 'max_eso=',max(pt(vec_GTV)) 
print,'25_eso=',prank(pt(vec_GTV),25) 
print,'75_eso=',prank(pt(vec_GTV),75) 
 
 
node=reform(struk_new(n, *,*,*)) 
vec_GTV=where(node) 
 
print,roi_name(n) 
print,'min_node=',min(pt(vec_GTV)) 
print,'median_node=',median(pt(vec_GTV)) 
print, 'mean_node=',mean(pt(vec_GTV)) 
print, 'max_node=',max(pt(vec_GTV)) 
print,'25_node=',prank(pt(vec_GTV),25) 
print,'75_node=',prank(pt(vec_GTV),75) 
 
rl=reform(struk_new(r, *,*,*)) 
vec_GTV=where(rl) 
;vec_gtv=where(in_ct+vec_gtv) 
print,roi_name(r) 
print,'min_rl=',min(pt(vec_GTV)) 
print,'median_rl=',median(pt(vec_GTV)) 
print, 'mean_rl=',mean(pt(vec_GTV)) 
print, 'max_rl=',max(pt(vec_GTV)) 
print,'25_rl=',prank(pt(vec_GTV),25) 
print,'75_rl=',prank(pt(vec_GTV),75) 
 
ll=reform(struk_new(l, *,*,*)) 
vec_GTV=where(ll) 
;vec_gtv=where(in_ct+vec_gtv) 
 
print,roi_name(l) 
print,'min_ll=',min(pt(vec_GTV)) 
print,'median_ll=',median(pt(vec_GTV)) 
print, 'mean_ll=',mean(pt(vec_GTV)) 
print, 'max_ll=',max(pt(vec_GTV)) 
print,'25_ll=',prank(pt(vec_GTV),25) 
print,'75_ll=',prank(pt(vec_GTV),75) 
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bone=reform(struk_new(b, *,*,*)) 
vec_GTV=where(bone) 
 
print,roi_name(b) 
print,'min_bode=',min(pt(vec_GTV)) 
print,'median_bone=',median(pt(vec_GTV)) 
print, 'mean_bone=',mean(pt(vec_GTV)) 
print, 'max_bone=',max(pt(vec_GTV)) 
print,'25_bone=',prank(pt(vec_GTV),25) 
print,'75_bone=',prank(pt(vec_GTV),75) 
endfor 
print,'g=',g,'h=',h, 'e=',e,'n=',n,'r=',r,'l=',l,'b=',b 
 
;; %%%%%%%%%%%%%%%%%%%%%%dose vs SUV %%%%%%%%%%%%%%%%%%%%%%%% 
 
do_ca=findgen(30)*1 
m_d=do_ca*0.0 
m_SUV=do_ca*0.0 
;sig_d=m_d 
;sig_SUV=m_SUV 
 
for i=1, 29 do begin 
 index=where(rct_image ge 200 and rct_image lt 800 and d_mod le do_ca(i) and d_mod gt do_ca(i-1)) 
 m_d(i)=mean(d_mod(index)) 
 sig_d(i)=stdev(d_mod(index)) 
 m_SUV(i)=mean(pt_mod_new(index)) 
 sig_SUV(i)=stdev(pt_mod_new(index)) 
pt=reform(pt_images(*,*,*, 1)) 
GTV=reform(struk_new(13, *,*,*)) 
vec_GTV=where(GTV and d_mod le do_ca(i) and d_mod gt do_ca(i-1)) 
m_d(i)=mean(d_mod(vec_GTV)) 
m_suv(i)=mean(pt(vec_GTV)) 
endfor 
 
;;match lungs 
 
index=fltarr(dim_x,dim_y,dim_z) 
for i=0, nses-1 do begin 
 ct_1=reform(ct_images(*,*,*,i)) 
 ct_1(where(ct_1 gt 800))=0 
 ct_1(where(ct_1 lt 100))=0 
 ct_1(where(ct_1))=1 
 TVSCL,CT_1(*,*,80) 
 STOP 
 index=index+ct_1 
 
endfor 
 
 
for k=0, nses-1 do begin 
r=11 
l=12 
print,k+1 
print,roi_name(R) 
pt=reform(pt_images(*,*,*, k)) 
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RL=reform(struk_new(R, *,*,*)) 
RL(where(RL))=1 
window,0 
tvscl,rl(*,*,80) 
index_R=index+RL 
RL(where(index_R eq nses+1))=1 
RL(where(index_R lt nses+1))=0 
window,1 
tvscl,RL(*,*,80) 
vec_GTV=where(RL) 
print,roi_name(r) 
print,'min_rl=',min(pt(vec_GTV)) 
print,'median_rl=',median(pt(vec_GTV)) 
print, 'mean_rl=',mean(pt(vec_GTV)) 
print, 'max_rl=',max(pt(vec_GTV)) 
print,'25_rl=',prank(pt(vec_GTV),25) 
print,'75_rl=',prank(pt(vec_GTV),75) 
 
ll=reform(struk_new(l, *,*,*)) 
LL(where(LL))=1 
window,2 
tvscl,ll(*,*,80) 
index_L=index+LL 
LL(where(index_L eq nses+1))=1 
LL(where(index_L lt nses+1))=0 
window,3 
tvscl,LL(*,*,80) 
vec_GTV=where(LL) 
 
print,roi_name(l) 
print,'min_ll=',min(pt(vec_GTV)) 
print,'median_ll=',median(pt(vec_GTV)) 
print, 'mean_ll=',mean(pt(vec_GTV)) 
print, 'max_ll=',max(pt(vec_GTV)) 
print,'25_ll=',prank(pt(vec_GTV),25) 
print,'75_ll=',prank(pt(vec_GTV),75) 
ENDFOR 
STOP 
;;; %%%%%%%%%%%%%%%%%%%%%%dose vs SUV %%%%%%%%%%%%%%%%%%%%%%%% 
;%%%%white background%%%% 
Device, Decomposed=0 ; Index color model. 
 LoadCT, 0 ; Normal black to white color table. 
 TVLCT, r, g, b, /Get 
TVLCT, Reverse(r), Reverse(g), Reverse(b) 
;%%%%%%% 
do_ca=findgen(30)*1 
m_d=do_ca*0.0 
m_SUV=do_ca*0.0 
 
for k=0, nses-1 do begin 
 for i=1, 29 do begin 
 
 pt=reform(pt_images(*,*,*, k)) 
 GTV=reform(struk_new(11, *,*,*)) 
 GTV(where(GTV))=1 
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 index_x=index+GTV 
 GTV(where(index_x eq nses+1))=1 
 GTV(where(index_x lt nses+1))=0 
 
 vec_GTV=where(GTV and d_mod le do_ca(i) and d_mod gt do_ca(i-1)) 
 m_d(i)=mean(d_mod(vec_GTV)) 
 m_suv(i)=mean(pt(vec_GTV)) 
 endfor 
!y.omargin=[3,3] 
plot, m_d, m_SUV, xtitle='Dose (Gy)',ytitle= 'SUV!Imean!N in the left lung',$ 
subtitle='!CPatient ID: 04. Second treatment session',$ 
title='"SUV!Imean!N versus Radiation 
Dose"!C',FONT=1,xtickinterval=2.0,thick=1.5,xcharsize=1.1,ycharsize=1.1,charsize=1.3,xstyle=8,ystyle=8.0,psym
=4 
 
endfor 
 
end 
 
;; %%%%%%%%%%%%%%%%%%%%%%dose vs delta SUV %%%%%%%%%%%%%%%%%%%%%%%% 
%%%%white background%%%% 
Device, Decomposed=0 ; Index color model. 
 LoadCT, 0 ; Normal black to white color table. 
 TVLCT, r, g, b, /Get 
TVLCT, Reverse(r), Reverse(g), Reverse(b) 
;%%%%%%% 
do_ca=findgen(30)*1 
m_d=do_ca*0.0 
m_SUV=do_ca*0.0 
 
for i=1, 29 do begin 
 ;pt_1=reform(pt_images(*,*,*, 2)) 
 ;pt_2=reform(pt_images(*,*,*, 1)) 
 pt_delta=reform(pt_images(*,*,*, 1)-pt_images(*,*,*, 2)) 
 GTV=reform(struk_new(11, *,*,*)) 
 GTV(where(GTV))=1 
 index_x=index+GTV 
 GTV(where(index_x eq nses+1))=1 
 GTV(where(index_x lt nses+1))=0 
 
 vec_GTV=where(GTV and d_mod le do_ca(i) and d_mod gt do_ca(i-1)) 
 m_d(i)=mean(d_mod(vec_GTV)) 
 m_suv(i)=mean(pt_delta(vec_GTV)) 
endfor 
 
end 
;%%%%%%%%%%%%%%%%%%%%%%plot data%%%%%%%%%%%%%%%%%%%%%%%%% 
;PRO ANALYSIS, file, im_ses 
 
slice=70 
ref_res=[3.0,3.0,3.0] 
 
i = '' 
READ, i, PROMPT='patient name: ' 
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file = FILEPATH('PAT'+i, ROOT_DIR='C:', SUBDIRECTORY='THORAT') 
 
cd, file+'\RESULTS' 
ct_files=file_search('CT*', count=nses) 
ses=intarr(nses) 
 
for i=0, nses-1 do ses(i)=fix(strmid(ct_files(i), 8, 1)) 
restore, ct_files(0) 
si=size(ct_mod) 
dim_x=si(1) 
dim_y=si(2) 
dim_z=si(3) 
ct_images=fltarr(dim_x, dim_y, dim_z, nses) 
 
ct_images(*,*,*, 0)=ct_mod 
endfor 
for i=1, nses-1 do begin 
 restore, ct_files(i) 
 ct_images(*,*,*, i)= ct_mod 
endfor 
 
for i=0, nses-1 do begin 
 window, i, xsize=3*dim_x, ysize=3*dim_y 
 tvscl, rebin(ct_images(*,*, slice, i),3*dim_x, 3*dim_y, /SAMPLE) 
endfor 
 
rct_file=file_search('RCT*') 
restore,rct_file 
 
d_file=file_search('D*') 
restore,d_file 
 
pt_files=file_search('PET*') 
pt_images=fltarr(dim_x, dim_y, dim_z, nses) 
for i=0, nses-1 do begin 
 restore, pt_files(i) 
 pt_images(*,*,*, i)=pt_mod 
 
endfor 
 
struk_file=file_search('struk*') 
restore, struk_file 
;print,roi_name 
 
;%%%%%%%%%%%% Analysis%%%%%%%%% 
index=intarr(dim_x,dim_y,dim_z) 
for i=0, nses-1 do begin 
 ct_1=reform(ct_images(*,*,*,i)) 
 ct_1(where(ct_1 gt 800))=0 
 ct_1(where(ct_1 lt 100))=0 
 ct_1(where(ct_1))=1 
 ;TVSCL,CT_1(*,*,80) 
 index=index+ct_1 
endfor 
index(where(index ne nses))=0 
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for k=0, nses-1 do begin 
pt=reform(pt_images(*,*,*, k)) 
ct_i=reform(ct_images(*,*,*, k)) 
 
n1=7 
 
node1=reform(struk_new(n1, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n1_EXP = DILATE(node1, smooth_struc) 
 
node2=reform(struk_new(n2, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n2_EXP = DILATE(node2, smooth_struc) 
 
node3=reform(struk_new(n3, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n3_EXP = DILATE(node3, smooth_struc) 
 
node4=reform(struk_new(n4, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n4_EXP = DILATE(node4, smooth_struc) 
 
node5=reform(struk_new(n5, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n5_EXP = DILATE(node5, smooth_struc) 
 
node6=reform(struk_new(n6, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n6_EXP = DILATE(node6, smooth_struc) 
node7=reform(struk_new(n7, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n7_EXP = DILATE(node7, smooth_struc) 
node8=reform(struk_new(n8, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n8_EXP = DILATE(node8, smooth_struc) 
node9=reform(struk_new(n9, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n9_EXP = DILATE(node9, smooth_struc) 
node10=reform(struk_new(n10, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n10_EXP = DILATE(node10, smooth_struc) 
node11=reform(struk_new(n11, *,*,*)) 
smooth_struc=intarr(3,3,3)+1 
n11_EXP = DILATE(node11, smooth_struc) 
 
 
vec_struc=where(node1) 
print,'minim_NODE1=   ',min(pt(vec_struc)) 
print,'25thp_NODE1=   ',prank(pt(vec_struc),25) 
print,'media_NODE1=   ',median(pt(vec_struc)) 
print,'mean_NODE1=   ',mean(pt(vec_struc)) 
print,'75thp_NODE1=   ',prank(pt(vec_struc),75) 
print,'maxim_NODE1=   ',max(pt(vec_struc)) 
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endfor 
 
g= 2 
l= 10 
r= 11 
h= 5 
e= 6 
b= 12 
 
 
 
GTV=reform(struk_new(g, *,*,*)) 
vec_struc=where(GTV) 
 
print,'minim_GTVVV=   ',min(pt(vec_struc)) 
print,'25thp_GTVVV=   ',prank(pt(vec_struc),25) 
print,'media_GTVVV=   ',median(pt(vec_struc)) 
print,'mean_GTVVV=   ',mean(pt(vec_struc)) 
print,'75thp_GTVVV=   ',prank(pt(vec_struc),75) 
print,'maxim_GTVVV=   ',max(pt(vec_struc)) 
print,'cminim_GTVVV=   ',min(ct_i(vec_struc)) 
print,'c25thp_GTVVV=   ',prank(ct_i(vec_struc),25) 
print,'cmedia_GTVVV=   ',median(ct_i(vec_struc)) 
print,'cmean_GTVVV=   ',mean(ct_i(vec_struc)) 
print,'c75thp_GTVVV=   ',prank(ct_i(vec_struc),75) 
print,'cmaxim_GTVVV=   ',max(ct_i(vec_struc)) 
 
smooth_struc=intarr(5,5,5)+1 
gtv_EXP = DILATE(GTV, smooth_struc) 
 
heart=reform(struk_new(h, *,*,*)) 
vec_struc=where(heart gt 0 and gtv_exp ne 1) 
 
print,'minim_HEART=   ',min(pt(vec_struc)) 
print,'25thp_HEART=   ',prank(pt(vec_struc),25) 
print,'media_HEART=   ',median(pt(vec_struc)) 
print,'mean_HEART=   ',mean(pt(vec_struc)) 
print,'75thp_HEART=   ',prank(pt(vec_struc),75) 
print,'maxim_HEART=   ',max(pt(vec_struc)) 
 
smooth_struc=intarr(3,3,3)+1 
heart_EXP = DILATE(heart, smooth_struc) 
 
eso=reform(struk_new(e, *,*,*)) 
vec_struc=where(eso gt 0 and gtv_exp ne 1) 
 
print,'minim_ESOPH=   ',min(pt(vec_struc)) 
print,'25thp_ESOPH=   ',prank(pt(vec_struc),25) 
print,'media_ESOPH=   ',median(pt(vec_struc)) 
print,'mean_ESOPH=   ',mean(pt(vec_struc)) 
print,'75thp_ESOPH=   ',prank(pt(vec_struc),75) 
print,'maxim_ESOPH=   ',max(pt(vec_struc)) 
 
smooth_struc=intarr(3,3,3)+1 
esoph_EXP = DILATE(eso, smooth_struc) 
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bone=reform(struk_new(b, *,*,*)) 
vec_struc=where(bone and gtv_exp ne 1) 
 
print,'minim_BONEM=   ',min(pt(vec_struc)) 
print,'25thp_BONEM=   ',prank(pt(vec_struc),25) 
print,'media_BONEM=   ',median(pt(vec_struc)) 
print,'mean_BONEM=   ',mean(pt(vec_struc)) 
print,'75thp_BONEM=   ',prank(pt(vec_struc),75) 
print,'maxim_BONEM=   ',max(pt(vec_struc)) 
 
smooth_struc=intarr(3,3,3)+1 
bone_EXP = DILATE(bone, smooth_struc) 
 
 
ll=reform(struk_new(l, *,*,*)) 
vec_struc=where(ll gt 0 and index gt 0 and gtv_exp ne 1 and heart_exp ne 1 and esoph_exp ne 1 and bone_exp ne 
1);$ 
;and n1_exp ne 1 and n2_exp ne 1 and n3_exp ne 1 and n4_exp ne 1  and n5_exp ne 1 and n6_exp ne 1 and n7_exp 
ne 1 $ 
; and n8_exp ne 1 and n9_exp ne 1 and n10_exp ne 1 and n11_exp ne 1) 
 
print,'minim_LLUNG=   ',min(pt(vec_struc)) 
print,'25thp_LLUNG=   ',prank(pt(vec_struc),25) 
print,'media_LLUNG=   ',median(pt(vec_struc)) 
print,'mean_LLUNG=   ',mean(pt(vec_struc)) 
print,'75thp_LLUNG=   ',prank(pt(vec_struc),75) 
print,'maxim_LLUNG=   ',max(pt(vec_struc)) 
print,'cminim_LLUNG=   ',min(ct_i(vec_struc)) 
print,'c25thp_LLUNG=   ',prank(ct_i(vec_struc),25) 
print,'cmedia_LLUNG=   ',median(ct_i(vec_struc)) 
print,'cmean_LLUNG=   ',mean(ct_i(vec_struc)) 
print,'c75thp_LLUNG=   ',prank(ct_i(vec_struc),75) 
print,'cmaxim_LLUNG=   ',max(ct_i(vec_struc)) 
 
rl=reform(struk_new(r, *,*,*)) 
vec_struc=where(rl gt 0 and index gt 0 and gtv_exp ne 1 and heart_exp ne 1 and esoph_exp ne 1 and bone_exp ne 
1);$ 
;and n1_exp ne 1 and n2_exp ne 1 and n3_exp ne 1 and n4_exp ne 1  and n5_exp ne 1 and n6_exp ne 1 and n7_exp 
ne 1 $ 
 ;and n8_exp ne 1 and n9_exp ne 1 and n10_exp ne 1 and n11_exp ne 1) 
print,'minim_RLUNG=   ',min(pt(vec_struc)) 
print,'25thp_RLUNG=   ',prank(pt(vec_struc),25) 
print,'media_RLUNG=   ',median(pt(vec_struc)) 
print,'mean_RLUNG=   ',mean(pt(vec_struc)) 
print,'75thp_RLUNG=   ',prank(pt(vec_struc),75) 
print,'maxim_RLUNG=   ',max(pt(vec_struc)) 
print,'cminim_RLUNG=   ',min(ct_i(vec_struc)) 
print,'c25thp_RLUNG=   ',prank(ct_i(vec_struc),25) 
print,'cmedia_RLUNG=   ',median(ct_i(vec_struc)) 
print,'cmean_RLUNG=   ',mean(ct_i(vec_struc)) 
print,'c75thp_RLUNG=   ',prank(ct_i(vec_struc),75) 
print,'cmaxim_RLUNG=   ',max(ct_i(vec_struc)) 
 
endfor 
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print,'GTV=',roi_name(G) 
print,'HEART=',roi_name(H) 
print,'ESOPHAGUS=',roi_name(E) 
print,'RLUNG=',roi_name(R) 
print,'LLUNG=',roi_name(L) 
print,'BONE=',roi_name(B) 
;print,roi_name(n1),roi_name(n2),roi_name(n3),roi_name(n4),roi_name(n5) 
 
end 
 
